

(19)



(11)

EP 3 037 819 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(43) Date of publication:

29.06.2016 Bulletin 2016/26

(51) Int Cl.:

G01N 33/53 (2006.01)

G01N 33/569 (2006.01)

(21) Application number: **14838699.8**

(86) International application number:

PCT/JP2014/071591

(22) Date of filing: **18.08.2014**

(87) International publication number:

WO 2015/025825 (26.02.2015 Gazette 2015/08)

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

(72) Inventors:

- **KUROSAWA, Yoshikazu**
Toyoake-shi
Aichi 470-1192 (JP)
- **OHSIMA, Nobuko**
Toyoake-shi
Aichi 470-1192 (JP)

(30) Priority: **23.08.2013 JP 2013172902**

(74) Representative: **Steinecke, Peter**

(71) Applicant: **Fujita Health University**
Aichi 470-1192 (JP)

Müller Fottner Steinecke
Rechtsanwalts- und Patentanwaltspartnerschaft
mbB
P.O. Box 1140
52412 Jülich (DE)

(54) **METHOD OF DETERMINING RESISTANCE TO INFLUENZA VIRUS**

(57) Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type A influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the VH1-69 gene in a biological sample originating from a subject.

EP 3 037 819 A1

Description

TECHNICAL FIELD

[0001] The present invention relates to an examination targeting an antibody. Specifically, the present invention relates to a method of determining resistance to an influenza virus using a specific antibody as an indicator. The present invention is useful as a countermeasure for handling an outbreak (pandemic) of influenza. The present application claims priority based on Japanese Patent Application No. 2013-172902 filed on August 23, 2013, and the entirety of the contents of said patent application is herein incorporated by reference.

BACKGROUND ART

[0002] Influenza is an infectious disease of respiratory track that affects millions of people every year. Since antibodies (Abs) play important roles in protection against influenza virus, preventive vaccination has been the most efficient measure of influenza control. While hemagglutinin (HA) is the main target for virus-neutralizing Abs, it mediates virus entry into cells at two steps (Non-patent literature 1). First, HA binds to the cell receptor, sialic acid. After internalization of viruses by endocytosis, HA undergoes a drastic conformational change induced by low pH. It has been shown that neutralizing Abs have one of the following activities: prevention of binding reaction between HA and sialic acid (Non-patent literature 2) and prevention of low-pH-induced conformational change of HA (Non-patent literature 3). The former (hereinafter referred to as "1st type neutralizing Abs") binds to the site near sialic acid-binding pocket on the globular head in HA, and the latter binds to the stem region of HA. Since the dominant immune response is the first type, and mutations can be easily introduced into the target sites without losing the receptor-binding activity, variant viruses that have acquired resistance to these Abs become dominant and cause annual epidemics. Historically, it was long believed that all effective neutralizing Abs are the first type, and therefore, vaccine strains should have been changed almost every year in order to remain effective. As long as the type of vaccine strain well matches up to that of circulating virus, vaccination is effective for preventing virus infection.

[0003] Mode of response against infection of influenza virus is very heterogeneous among human population. For example, there are many persons who had suffered from influenza several times in their childhood but never suffered afterwards without vaccination. In 2009, a swine-origin H1N1 influenza virus (S-OIV) emerged and rapidly spread among human population, resulting in its classification as the first pandemic in the 21st century (Non-patent literature 4). It has been generally believed that humans lack immunity to the newly appearing influenza virus at the outbreak of pandemic because they are naive to the virus. In the case of S-OIV, however, long-lived memory B cells that produce broadly neutralizing Abs not only against seasonal H1N1 viruses but also S-OIV are found in many of the elderly (Non-patent literature 5 to 7).

PRIOR ART DOCUMENTS

NON-PATENT DOCUMENTS

[0004]

Non-Patent Document1: Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Ann. Rev. Biochem.* 69, 531-569 (2000).

Non-Patent Document2: Knossow, M. et al. Mechanism of neutralization of onfluenza virus infectivity by antibodies. *Virology* 302, 294-298 (2002).

Non-Patent Document3: Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J. Virol.* 67, 2552-2558 (1993).

Non-Patent Document4: Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* 324, 1557-1561 (2009).

Non-Patent Document5: Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.* 361, 1945-1952 (2009).

Non-Patent Document6: Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med.* 208, 181-193 (2011).

Non-Patent Document7: Li, G.M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. *Proc. Natl. Acad. Sci.* 109, 9047-9052 (2012).

SUMMARY OF THE INVENTION

PROBLEMS TO BE SOLVED BY THE INVENTION

5 **[0005]** Currently, the following countermeasures for a pandemic are taken in Japan.

- (1) Stockpiling of a large amount of antiviral drug for influenza (a neuraminidase inhibitor)
- (2) Stockpiling of a large amount of prepandemic vaccine
- (3) Construction of a system for the production of a pandemic vaccine

10 **[0006]** Regarding (1), there are a problem that the term in which the antiviral drug for influenza is effective in the processes of infection and onset of disease is limited, and a problem of the emergence of a drug resistance virus. Regarding (2), there is a problem that the type (antigenicity) of a virus that actually causes a pandemic cannot be properly expected. Regarding (3), although switching from conventional proliferation of a virus in chicken egg to proliferation of

15 a virus in cultured cells, there is a limit in shortening of a time for the production of a vaccine.
[0007] In order to make a breakthrough in the above-mentioned current situations, the present invention aims at providing an effective means as a countermeasure against a pandemic of an influenza virus.

MEANS FOR SOLVING PROBLEM

20 **[0008]** In order to analyze total repertoire of neutralizing Abs against influenza viruses in humans, we developed the following experimental strategy in our previous study (Reference 8). A large number of B lymphocytes are collected by apheresis from a donor, and a huge Ab library is constructed by using the phage-display technology. The library is screened with formalin-treated virus particles. The clones that have both binding activity and neutralizing activity to the virus are isolated and their strain specificity is extensively characterized. Although only B lymphocytes that are circulating in peripheral blood are analyzed in our experimental system, the results obtained appeared to represent the total repertoire of neutralizing Abs formed in the donor's body (Reference 8). We applied this strategy to extensively analyzed total repertoire of antibodies against HA that were induced in the body of such a person after vaccination with 2009 H1N1 pandemic influenza virus. They are classified into two types with few exceptions. The first type, the products by B cells newly induced through vaccination, binds to the surroundings of a sialic acid-binding pocket. The second type, the products by long-lived memory B cells established before vaccination, utilized 1-69 V_H gene, binds to the stem of HA. The second type neutralizes both H1N1 and H5N1 viruses. Furthermore, it was suggested that it is highly possible that the second type antibody has recognized an epitope that is difficult to change, and thus respond to the virus infection for a long term. Considering the above-mentioned results, a strategy to prepare for a pandemic of influenza should be designed with consideration for an antibody possessed by an individual person (an effective neutralization antibody, that is, the presence or absence of possession of the second type antibody), and it can be said that "an antibody using VH1-69 gene" is useful as an indicator therefor. That is, if an antibody using VH1-69 gene is detected and the result thereof is utilized, then an effective and efficient countermeasure for a pandemic can be attained. In addition, it was also clarified by the consideration of the present inventors that the antibody using VH1-69 gene can be detected as a secreted antibody, that the antibody using VH1-69 gene increases by vaccination, and the like, and it was directly shown that the antibody using VH1-69 gene functions as a neutralization antibody by the fact that a monoclonal antibody (K1-18), which inhibits the binding of the antibody using VH1-69 gene and hemagglutinin, inhibited the virus neutralizing activity.

35 **[0009]** Based mainly on the above-mentioned results, the following inventions are provided.

45 [1] A method of determining resistance to a type A influenza virus by using the presence or absence of an antibody using VH1-69 gene in a biological sample derived from a subject.

[2] The method according to [1], including the following steps (1) to (3):

- (1) a step of bringing a biological sample of a subject that has received an influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene;
- (2) a step of detecting a generated immune complex;
- (3) a step of determining the intensity of the resistance to the type A influenza virus based on the detection result in the step (2), in which the amount of the detected immune complex serves as an indicator of the intensity of the resistance to the type A influenza virus.

55 [3] The method according to [2], further including the following step:

- (4) a step of detecting an immune complex generated by bringing a biological sample of a subject before

receiving the influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene, comparing the amount of the immune complex with the amount of the immune complex detected in the step (2), and determining the intensity of the resistance based on the result of the comparison.

[4] The method according to [2] or [3], in which the biological sample is a blood sample.

[5] The method according to any one of [1] to [4], in which the type A influenza virus is one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H3N2, H5N1, H5N2, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H9N1.

[6] The method according to any one of [1] to [4], in which the type A influenza virus is one or more viruses selected from the group consisting of H1N1, H2N2, H3N2 and H5N1.

[7] The method according to any one of [1] to [4], in which the type A influenza virus is one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H5N1 and H5N2.

[8] A kit for detecting resistance to a type A influenza virus, including an anti-idiotypic antibody that specifically recognizes an antibody using VH1-69 gene.

BRIEF DESCRIPTION OF THE DRAWINGS

[0010]

[Fig. 1] Activities of representative clones classified into 63 groups. Numbers in the first three columns correspond to Group number of those isolated by the screenings, number of unique clones in each group, and number of isolated clones in each group, respectively. Germline gene was identified by comparison between the amino acid sequence of V_H of the representative clone and those of all the germline V_H genes, and the identity (%) was indicated. The amino acid sequence of CDR3 was shown. The binding activity to four H1N1 (NC99, SI06, Bri07 and Cal09) and one H3N2 virus particles was examined by ELISA. Absorbance at 492 nm was marked as follows: ≥1.00 (red), 0.50-0.99 (orange), 0.10-0.49 (yellow); The virus neutralizing activity of 100 or 250 μg/ml Fab-PP Ab against H1N1, H5N1, and H3N2 viruses was examined by the focus reduction test. The reduction rate was shown as percentage and marked as follows: ≥60% (dark blue), 40-60% (blue), 20-40% (light blue); The HI activity of Fab-PP Ab was measured using two H1N1 (Bri07 and Cal09) viruses. The lowest concentration (μg/ml) of Fab-PP Abs to inhibit hemagglutination was shown. The amino acid sequences of CDR3s are, from the top to the bottom, as follows: DTTVTNEEINFYYGMDV (SEQ ID NO:1), DTEVTNEEINFYYGMDV (SEQ ID NO:2), DTEVTSEEINFYYGMDV (SEQ ID NO:3), DTTVTSEEINFYQGMDV (SEQ ID NO:4), EFGANGEDIYFYHGMDV (SEQ ID NO:5), SIGGYDGEGIFYNHYGMDV (SEQ ID NO:6), DEWFGELGSSGMDV (SEQ ID NO:7), DFAGEGHGSGSVDY (SEQ ID NO:8), SATSYRDYLD R DFFYYALDV (SEQ ID NO:9), SATSYRDYLD R DFFYYALDV (SEQ ID NO:10), DHLNSEIVATITGFLDY (SEQ ID NO:11), DKLNSEMVATITGFLDY (SEQ ID NO:12), DKLNSEMVATITGFMDY (SEQ ID NO:13), DKLNSDEVTTITGFLDY (SEQ ID NO:14), DNLNSELVATITGFLDH (SEQ ID NO:15), DNLNSDEVATISGFLDY (SEQ ID NO:16), DYLNSEMVATITGFLDS (SEQ ID NO:17), EPSNTEDIRGIEGVFDY (SEQ ID NO:18), DAYSSGDTYYYGLDV (SEQ ID NO:19), DRGTGEQIAVVTALIDY (SEQ ID NO:20), HGYGDYVGYFDY (SEQ ID NO:21), VLRWLGEEDADAFDI (SEQ ID NO:22), GFGMVGDVDDLYNGMDV (SEQ ID NO:23), VQRPYGDYAAGAFDI (SEQ ID NO:24), VQRPYGDYITGAFDI (SEQ ID NO:25), RTWYYDGS GPDPSRDAFDI (SEQ ID NO:26), DLGN GEDIAVQP GTIGVDY (SEQ ID NO:27), DLGN GEDIAVQP GTTGVDY (SEQ ID NO:28), DLGN GEDIVVQPATIGVDY (SEQ ID NO:29), GTEVTTEEIYFYGMDV (SEQ ID NO:30), GTEVTTEEINFYYGMDV (SEQ ID NO:31), AEKWLADYFYYFGMDV (SEQ ID NO:32), DREESLFAGAIYNY YDMDV (SEQ ID NO:33), KGGAKLLYFDWLASAFDI (SEQ ID NO:34), GPNYYENFFDY (SEQ ID NO:35), GPNYYESYFDY (SEQ ID NO:36), GPNYYENYFDF (SEQ ID NO:37), GPNYYE SYLDF (SEQ ID NO:38), GPNYFESYFDN (SEQ ID NO:39), GPNYYETYLDN (SEQ ID NO:40), GPHYYESHLDY (SEQ ID NO:41), GPHYYSYFDS (SEQ ID NO:42), GNTYYSSYFDQ (SEQ ID NO:43), GSTYYSSYFDQ (SEQ ID NO:44), SGTYYSYFDS (SEQ ID NO:45), SGTYYSYLD (SEQ ID NO:46), SGTYYSVFFDY (SEQ ID NO:47), SGSYYPDYFQY (SEQ ID NO:48), SPTYYPGALDM (SEQ ID NO:49), APLIYNWYFDL (SEQ ID NO:50), APLIYNWYDL (SEQ ID NO:51), HPTYHYGSAMDY (SEQ ID NO:52), HPTYYFGSAMEY (SEQ ID NO:53), HPTYYYGSPMDY (SEQ ID NO:54), HPMYHYGSAMDY (SEQ ID NO:55), HSGYHLIGYFDS (SEQ ID NO:56), EGGY YGSGPLDS (SEQ ID NO:57), NSGYHISGFYLDY (SEQ ID NO:58), SLGYHTQYNGMDV (SEQ ID NO:59), HPTYHFDKSGYRFDS (SEQ ID NO:60), SRGYSFGYGT DYFDY (SEQ ID NO:61), NYYGSGTYFNDAFDI (SEQ ID NO:62), YQSSDY NSEYFQH (SEQ ID NO:63)

[Figure 2] Competitive inhibition of binding to HA among the Abs newly induced by vaccination. The binding activity of Fab-PP Ab (indicated at upper side) to Cal09 virus particles was measured by ELISA under the presence of 10-times high concentration of Fab-cp3 Ab (indicated at the left side). F008-009 and F033-367 are not anti HA Abs and used as controls. The binding inhibition was calculated as follows: the absorbance value under the presence of

F008-009cp3 was used as 100 % binding and the degree of reduction in the absorbance value under the presence of Fab-cp3 of Ab was measured and shown as percent inhibition. Percent inhibition was marked as follows: $\geq 70\%$ (white), 50-70% (grey), 0-50% (dark grey). The experiment was performed at least three times in duplicate.

[Figure 3] Inhibition of the binding of C179 to HA by type 2 Abs isolated in this study. Binding of C 179 to Bri07 virus particles was examined under presence of a 10-times high concentration of various Fab-cp3 Abs by ELISA. F008-009 and F033-367 are not anti HA Abs and used as negative controls. Group number was indicated under the name of clone. The experiment was performed two times in duplicate and the error bars show standard deviation.

[Figure 4] Schedule of vaccination and blood collection. In 2009, a donor born in 1947 was vaccinated with A/California/7/2009 pandemic vaccine strain two times (on November 2 and 16). Blood was collected from this donor two times before vaccination (on October 30 and November 2), a time after 1st vaccination (on November 9) and 5 times after 2nd vaccination (on November 17, 23, 30, December 7, and 14). Large phage Ab libraries were prepared from blood collected on October 30 (before vaccination) and December 14 (after vaccination), respectively.

[Figure 5] The amino acid sequence of VH (FR1-CDR1-FR2-CDR3-FR4) of each clone. SEQ ID NOs are 64-126 from the top to the bottom.

[Figure 6] HI and virus neutralizing activity of serum against H1N1 and H5N1 viral strains. For measurement of virus neutralizing activity of serum, VN and M-VN method was used. The results were indicated as the reciprocal of the highest dilution of serum to inhibit hemagglutination for HI activity and to show 50% focus reduction rate for virus neutralization test. Serums before vaccination were 2009.10.30 and 2009.11.2. ND means not-determined.

[Figure 7] Virus neutralizing activity of serum in the presence of K1-18 Ab. The results were indicated as the reciprocal of the highest dilution of serum to show 50% focus reduction rate. Serum before vaccination was 2009.11.2.

[Figure 8] The characteristics of K1-18 antibody. (a) The binding activity of K1-18 antibody against antibodies using VH1-69 gene. The binding activity of K1-18 antibody against antibodies using VH1-69 gene was measured by ELISA. F004-122, F009-165, F021-112, F021-256, F035-095 and F058-031 do not use a VH1-69 gene. The group numbers are indicated under the clone names. (b) The binding activities of the respective antibodies against virus particles in the presence of K1-18. The binding activities of the antibodies using VH1-69 gene against Bri07 virus particles were measured by ELISA in the presence of K1-18 antibody (100 or 200 $\mu\text{g/ml}$). F008-009 is used as not an anti-HA antibody but a negative control. The group numbers are indicated under the clone names. The experiments were conducted with duplication, and a standard deviation is indicated by an error bar.

DETAILED DESCRIPTION OF THE INVENTION

1. Method for determining resistance against type A influenza virus

[0011] The first aspect of the present invention relates to a method for determining resistance to a type A influenza virus. According to the present invention, the resistance of a subject to a type A influenza virus can be determined by an objective indicator. The method of the present invention is effective as a means for a countermeasure for handling a pandemic of influenza which may occur in the future, and thus is of extremely great value. In the method of the present invention, the resistance of a subject to a type A influenza virus is determined by using the presence or absence of an antibody using VH1-69 gene in a biological sample derived from the subject as an indicator, based on the finding that an antibody using VH1-69 gene broadly shows a neutralizing activity against type A influenza viruses, and the finding that B cells that produce an antibody using VH1-69 gene remain as memory cells and play an important role in the protection of a living body from type A influenza (regarding the details, see the Examples mentioned below).

[0012] Type A influenza viruses are roughly classified into two groups depending on the types of HA molecules: group 1 consisting of H2, H5, H1 and H6 (these are H1 clusters; H1a) and H13, H16 and H11 (these are H1 clusters; H1b), and group 2 consisting of H8, H12 and H9 (these are H9 clusters), H4, H14 and H3 (these are H3 clusters) and H15, H7 and H10 (these are H7 clusters). The method of the present invention exhaustively targets these type A influenza viruses. However, in one embodiment, one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H3N2, H5N1, H5N2, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H9N1 is/are targeted. In another embodiment, one or more viruses selected from the group consisting of H1N1, H2N2, H3N2 and H5N1, which are specifically deemed to be in great need for a countermeasure for a pandemic, are targeted. Furthermore, in still another embodiment, group 1 viruses are targeted, based on the fact that an epitope that is shared among group 1 viruses was recognized by the respective antibodies using VH1-69 gene (the antibodies found in the sample derived from a subject in the experiment

shown in the Examples). That is, in this embodiment, one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H5N1 and H5N2 is/are targeted.

[0013] In the determination method of the present invention, the presence or absence of an antibody using VH1-69 gene serves as an indicator. In other words, the resistance to a type A influenza virus is determined by the presence, amount, repertoire and the like of the antibody using VH1-69 gene.

[0014] A VH1-69 gene can generate an antibody that broadly shows a neutralizing activity by forming an antigen binding site even without a VL domain. "Antibody using VH1-69 gene" is an antibody having a VH region in which a VH1-69 gene, which is a Germline gene, is used. The VH1-69 gene codes for FR1, CDR1, FR2, CDR2 and FR3 that constitute the VH region. Accordingly, in "antibody using VH1-69 gene", high homology (commonality) is recognized in the amino acid sequence of from FR1 to FR3. Furthermore, the antibody using VH1-69 gene is characterized by the amino acid at the position 53 and the amino acid at the position 54, and this characteristic is considered to be important for the physiological function of "antibody using VH1-69 gene". In the antibody using VH1-69 gene, the amino acid residue at the position 53 is generally a hydrophobic amino acid (isoleucine, methionine, leucine, valine or the like), and the amino acid residue at the position 54 is also a hydrophobic amino acid (phenylalanine, leucine or the like). Typically, the position 53 amino acid of the antibody using VH1-69 gene is isoleucine, and the position 54 amino acid is phenylalanine. The sequence of the VH1-69 gene (coding for FR1 to FR3) is shown in SEQ ID NO: 127. Furthermore, the amino acid sequence encoded by the VH1-69 gene (FR1 to FR3) is shown in SEQ ID NO: 128.

[0015] The subject is not specifically limited, and humans of all ages may be the subject. The biological sample is also not specifically limited, and a biological sample in which an antibody can be detected is used. Examples of the biological sample are blood, blood plasma, blood serum, nasal secretion and saliva. Preferably, for the reasons of easy preparation, low invasiveness and the like, blood samples are used. Among the blood samples, it is specifically preferable to adopt blood serum or blood plasma as the sample. The biological sample may be prepared according to a conventional method.

[0016] In the method of the present invention, the following steps (1) to (3) are typically conducted.

(1) a step of bringing a biological sample of a subject that has received an influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene;

(2) a step of detecting a generated immune complex;

(3) a step of determining the intensity of the resistance to a type A influenza virus based on the detection result in the step (2), in which the amount of the detected immune complex serves as an indicator of the intensity of the resistance to the type A influenza virus.

[0017] In the step (1), a biological sample of a subject that has received an influenza vaccine, which has been prepared in advance, is brought into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene. The step (1) is an antigen-antibody reaction in vitro, and if an antibody using VH1-69 gene is present in the biological sample, then an immune complex is formed with an anti-idiotypic antibody.

[0018] Various viral strains can be used for the influenza vaccine. For example, inactivated vaccine, or live vaccines of H1N1 influenza (for example, A/California/7/2009pdm strain, A/Suita/1/2009pdm strain, A/New Caledonia/20/1999 strain, A/Solomon Islands/3/2006 strain, A/Brisbane/59/2007 (Bri07) strain), H3N2 influenza (for example, A/Panama/2007/1999 strain), H5N1 influenza (for example, A/Indonesia/5/2005/PR8-IBCDC-RG2 strain) can be used.

[0019] It is preferable to use a biological sample that has been collected at the timepoint when 5 days to 3 weeks have elapsed from vaccination so that the antibody that has been induced by the vaccination is sufficiently contained in the biological sample. A biological sample after plural times (for example, twice) of vaccination may also be used, and in such case, a biological sample that has been collected at the timepoint when 5 days to 3 weeks have elapsed from the final vaccination is generally used.

[0020] For the step (1), as a detection antibody, an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene is used. The anti-idiotypic antibody is an antibody that specifically recognizes a complementarity-determining region (CDR) in an antibody, and an anti-idiotypic antibody that is specific to an antibody using VH1-69 gene is used in the present invention. As mentioned above, the antibody using VH1-69 gene is characterized by the amino acid at the position 53 (typically isoleucine) and the amino acid at the position 54 (typically phenylalanine). Accordingly, it is preferable to use an anti-idiotypic antibody that specifically recognizes regions including these amino acids. The anti-idiotypic antibody used in the present invention may be prepared by using a known method, such as an immunological technique, a phage display process, a liposome display process or the like. There are companies or authorities for providing a service of contract preparation of antibodies (for example, Immuno-Biological Laboratories Co, Ltd. and APRO Science Inc.), and the anti-idiotypic antibody may also be prepared by utilizing the service. The anti-idiotypic antibody may be any of a polyclonal antibody, an oligoclonal antibody (a mixture of several to several tens of antibodies) and a monoclonal antibody, and a monoclonal anti-idiotypic antibody is preferably used.

[0021] The biological sample and anti-idiotypic antibody are brought into contact by adding the anti-idiotypic antibody to the biological sample, or by adding the biological sample to an element (for example, a well) on which the anti-idiotypic

antibody has been immobilized, or the like. The specific embodiment of the contacting, the conditions for the contacting, and the like may be suitably preset depending on the measurement method to be adopted.

[0022] In the step (2), the immune complex generated by the step (1) is detected. As the detection method (measurement method), a latex agglutination method, a fluoroimmunoassay (FIA), an enzyme immunoassay (EIA), a radioimmunoassay (RIA) and a Western blotting can be exemplified. As preferable detection method, FIA and EIA (including ELISA) can be exemplified. According to these methods, the detection can be conducted at high sensitivity, rapidly and conveniently. In FIA, a fluorescence-labeled antibody is used, and the immune complex is detected by using fluorescence as a signal. On the other hand, in EIA, an enzymatically-labeled antibody is used, and the immune complex is detected by using color development or luminescence based on an enzymatic reaction. The process is not limited to a non-competitive process, and a competitive process may also be used.

[0023] In the step (3), the intensity of the resistance to the type A influenza virus is determined based on the detection result in the step (2). In the present invention, the amount of the immune complex detected during the determination is deemed as an indicator of the resistance to the type A influenza virus. Typically, the intensity of the resistance to the type A influenza virus is determined based on the amount of the detected immune complex. The determination herein can be conducted automatically/mechanically without the judgement of a person having specialized knowledge such as a medical practitioner or a laboratory technician, as is apparent from the determination criteria therefor. Examples of the specific determination criteria are shown below.

<Examples of determination criteria>

[0024]

- (a) If an immune complex is detected, then resistance to an type A influenza virus is present.
- (b) If an immune complex is detected, then resistance to an type A influenza virus is intense.
- (c) Resistance to an type A influenza virus is more intense at a larger amount of an immune complex.

(Example of qualitative determination 1)

[0025] When a detected value is higher than a criterion value, it is determined that "resistance to a type A influenza virus is present", whereas when a detected value is lower than a criterion value, it is determined that "resistance to a type A influenza virus is absent".

(Example of qualitative determination 2)

[0026] When a detected value is higher than a criterion value, it is determined that "resistance to a type A influenza virus is intense", whereas when a detected value is lower than a criterion value, it is determined that "resistance to a type A influenza virus is weak".

(Example of qualitative determination 3)

[0027] When detectable (in the case of positive), it is determined that "resistance to a type A influenza virus is present", whereas when undetectable (in the case of negative), it is determined that "resistance to a type A influenza virus is absent".

(Example of qualitative determination 4)

[0028] When detectable (in the case of positive), it is determined that "resistance to a type A influenza virus is intense", whereas when undetectable (in the case of negative), it is determined that "resistance to a type A influenza virus is weak".

(Example of quantification determination)

[0029] As shown below, the intensity of resistance is preset for every scope of detected values, and the resistance is determined from a detected value.

Measured value < a: resistance is absent

$a \leq$ measured value < b: resistance is weak

$b \leq$ measured value < c: resistance is present but is not sufficient

$c <$ measured value: resistance is intense

[0030] Although the intensity is classified into four stages, the number of the classification can be optionally preset. An example of the number of the classification is from 2 to 7, preferably from 3 to 6.

[0031] In an embodiment of the present invention, the resistance to a type A influenza virus is determined by comparing the biological sample before vaccination and the biological sample after the vaccination. That is, this embodiment also includes the following step (4).

[0032] (4) A step of detecting an immune complex generated by bringing a biological sample of a subject before receiving the influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene, comparing the amount of the immune complex with the amount of the immune complex detected in the step (2), and determining the intensity of the resistance based on the result of the comparison.

[0033] If increase in the amount of the immune complex is observed after the vaccination as a result of the comparison, it can be determined that the resistance to a type A influenza virus is intense. Furthermore, the responsiveness regarding the antibody using VH1-69 gene can also be figured out. Accordingly, by conducting the step (4), beneficial information, although it is auxiliary, can be obtained. Furthermore, in the case when the determination is conducted by the step (4), the subjects can be typically classified into the following four groups.

(a) Persons who have a large amount of an antibody using VH1-69 gene (a neutralization antibody against a type A influenza virus)

(b) Persons who have a small amount of an antibody using VH1-69 gene (a neutralization antibody against a type A influenza virus)

(c) Persons who do not have an antibody using VH1-69 gene (a neutralization antibody against a type A influenza virus)

(d) Persons for whom an antibody using VH1-69 gene (a neutralization antibody against a type A influenza virus) is not induced even after vaccination

[0034] If the subjects are classified into (a) to (d) as mentioned above, for example, the following countermeasures can be taken for the respective groups, and thus extremely effective and efficient countermeasure for handling a pandemic can be attained.

Group (a): Basically, a countermeasure is not necessary.

Group (b): Selective stimulation of the proliferation of cells that produce a targeted neutralization antibody by inoculation of a H5N1 influenza vaccine

Group (c): Induction of the production of a targeted neutralization antibody by inoculation of several kinds of different group 1 influenza virus vaccines.

Group (d): A human antibody that neutralizes group 1 influenza viruses is prepared as an antibody for prevention/treatment, and is administered as necessary.

2. Kit for determining resistance to influenza virus

[0035] The second aspect of the present invention relates to a kit that is used in the determination method of the present invention. The kit of the present invention includes an anti-idiotypic antibody that specifically recognizes an antibody using VH1-69 gene as a major constitutional element so as to detect or capture an antibody using VH1-69 gene. The anti-idiotypic antibody has been labeled as necessary so as to be suitable for the use thereof. Examples of label substances that can be used for the labeling of the antibody can include fluorescent pigments such as fluorescein, rhodamine, Texas Red and Oregon Green; enzymes such as horseradish peroxidase, microperoxidase, alkaliphosphatase and β -D-galactosidase; chemical or biological luminescent compounds such as luminol and acridine pigments; radioisotopes such as ^{32}P , ^{131}I and ^{125}I ; and biotin. A labeled secondary antibody that recognizes the anti-idiotypic antibody can also be included in the kit. In this case, a non-labeled anti-idiotypic antibody is generally used. The anti-idiotypic antibody may be immobilized. The insoluble substrate used for the immobilization is not specifically limited. For example, resins such as polystyrene resins, polycarbonate resins, silicon resins and nylon resins, and a water-insoluble substance such as glass can be used. The immobilization of antibody can be carried by physical adsorption or chemical adsorption.

[0036] Other agents (buffers, solvents, blocking agents, substrates for enzyme, coloring agents and the like) and/or apparatuses or instruments (a container, a reaction apparatus, a fluorescence reader and the like) for use in carrying out the determination method of the present invention may also be included in the kit. Furthermore, an influenza strain that is used as a control, for the preparation of a calibration curve, and the like may also be included in the kit. In addition, an instruction manual is generally attached to the kit of the present invention.

[Examples]

[0037] The following study was made aiming at creating a means that is effective as a countermeasure for handling

a pandemic of a type A influenza virus.

1. Methods and Materials

(1) Viruses

[0038] The following influenza viruses were used in this study. A/H1N1 pdm: A/California/7/2009pdm (Cal09), A/Suina/1/2009pdm (Sui09); A/H1N1: A/New Caledonia/20/1999 (NC99), A/Solomon Islands/3/2006 (SI06), A/Brisbane/59/2007(Bri07). A/H3N2: A/Panama/2007/1999. A/H5N1: A/Indonesia/5/2005/PR8-IBCDC-RG2. Abbreviations for the strains are shown in the parentheses.

(2) Construction of Ab library

[0039] Phage Ab libraries were constructed as described previously (Reference 8). Briefly, mononuclear cells from a donor born in 1947 were collected by apheresis from the equivalent of 3 L of blood before and after vaccination. They contained 8.0×10^8 B lymphocytes (before vaccination) and 1.2×10^9 B lymphocytes (after vaccination). Large combinatorial Ab libraries were constructed from them by using the phage-display method as described previously (Reference 17). The size of libraries were: before vaccination, 1.6×10^9 clones for H chain, 2.0×10^9 clones for L chain and 1.4×10^{10} for Fab; after vaccination, 3.2×10^9 clones for H chain, 1.3×10^9 clones for L chain and 2.6×10^{10} clones.

(3) Screening of the library

[0040] Phages bound to virus particles were selected by a panning method as described previously (References 17 and 18). In brief, formalin-treated virus particles of Cal09 or Bri07 strains were used as Ags in the screenings. After two and three time pannings, *E. coli* (DH12S) cells were infected with the eluted phages and spread onto the LB plates containing 100 μ g/ml ampicillin and 0.2% glucose. *E. coli* colonies harboring phagemid were picked up and grown in 2 x YT medium containing 100 μ g/ml ampicillin, 0.05% glucose and 1 mM isopropyl- β -D-thiogalactopyranoside at 30°C overnight. During growth of *E. coli*, the Fab-cp3 form of Ab was secreted into the medium (Reference 19). The culture supernatants containing Fab-cp3 molecules were subjected to ELISA against H1N1 virus used as Ag in the screening and H3N2 virus. Clones that bound only to H1 were selected and subjected to further analyses.

(4) ELISA

[0041] Formalin-treated virus particles were coated onto 96 well Maxisorp immunoplates (Nunc) and Fab-cp3 Ab in the supernatant of *E. coli* culture was added to each well. After incubation with rabbit anti-cp3 Ab (MBL), the wells were further incubated with peroxidase-conjugated goat anti-rabbit IgG (H + L chain; MBL). Then, HRP substrate (OPD; Wako) was added to each well and color of sample was developed. After stopping peroxidase reaction by adding H_2SO_4 , the absorbance of sample at 492 nm was measured.

(5) Sequence analysis

[0042] The nucleotide sequences of V_H fragments of isolated Ab clones were determined by using GenomeLab Dye Terminator Cycle Sequencing with Quick Start Kit (BECKMAN COULTER) and a CEQ2000 DNA Analysis System (BECKMAN COULTER). The T7ETZ (5'-TAATACGACTCACTATAGGG-3':SEQ ID NO:129) was used as V_H sequencing primer.

(6) Virus neutralization test

[0043] For measurement of virus neutralizing activity, focus reduction assay was performed by using single cycling (VN) or multiple cycling (M-VN) method. Two hundred or 500 μ g/ml of Fab-pp Abs or two-fold serial dilutions of serum were mixed with equal volume of 100 FFU of influenza virus, and applied to MDCK cells in 96 well plate. In VN method, after incubation with the mixture, the cells were washed with serum free MEM and cultured in MEM containing 0.4% BSA at 37°C for 15h. In M-VN method, after incubation, MEM containing 0.4% BSA, 5mg/ml of acetylated trypsin, and 0.5 % methyl cellulose of equal volume to the mixture was further added to the cells without removing the mixture and the cells were incubated at 37°C for 28h. Then the cells were fixed with ethanol and stained with PAP (peroxidase and anti-peroxidase) complex. Number of focus containing one and more cells (VN method) or four and more cells (M-VN method) per focus was counted. The results were indicated as the focus reduction rate (%) for Fab-pp Ab or the reciprocal of the highest dilution of serum to show 50% focus reduction rate for serum.

(7) Hemagglutination inhibition (HI) assay

[0044] The HI test was performed as described previously (Reference 20). In brief, serial dilutions of 160 µg/ml of purified Fab-PP or donor's serum in PBS were prepared. Serial dilutions of Fab-PP or serum were preincubated with 4 HA units of virus per well. 0.75 % of guinea pig red blood cells in PBS were added to each well, and the plate was incubated at room temperature for 30-60 min. The results were shown as the lowest concentration (µg/ml) of Fab-pp Ab or the reciprocal of the highest dilution of serum to inhibit hemagglutination.

(8) Competition ELISA

[0045] Competition ELISA was performed by using Fab-PP form of Ab or C179 for detection of binding activity to virus particles and Fab-cp3 form of Ab as a competitor. Fab-cp3 molecules in the supernatant of *E. coli* culture were concentrated 20-fold before use. Formalin-inactivated virus particles were coated onto a 96 well Maxisorp immunoplate. A total of 50 µl of Fab-PP at an optimized concentration was mixed with 50 µl of 20-fold concentrated Fab-cp3 and the mixture was added to a virus-coated well. Then, peroxidase-conjugated rabbit anti streptavidine Ab was added to each well as a second Ab. When C 179 at the final concentration of 0.25 µg/ml was used for detection of the binding activity to viral strain, each well was incubated with peroxidase-conjugated goat anti-mouse IgG (H + L chain; MBL) as a second Ab. Then, HRP substrate (OPD; Wako) was added to each well and color of sample was developed. After stopping peroxidase reaction by adding H₂SO₄, the absorbance of sample at 492 nm was measured.

(9) Preparation of K1-18antibody

[0046] Five kinds of Fab-pp types of 1-69 antibody (F081-007, F083-103, F083-115, F083-305 and F083-311) were each purified, injected once together with a complete Freund's adjuvant to a footpad of a mouse, and further injected once at after 11 days without an adjuvant. At 3 days after the second injection, the lymphocytes were isolated from the inguinal lymph node, and fused with myeloma cell line P3-X63AG8.653. The hybridoma was cloned, and the culture solution was screened by ELISA on various kinds of antibodies in which the above-mentioned 1-69 antibody and VH1-69 gene were not used. An antibody that binds to a plurality of antibodies using a VH1-69 gene but does not bind to an antibody which does not use VH1-69 gene was selected. The isolation of K1-18 antibody was carried out by Monoclonal Antibody Laboratory (Sapporo, Japan).

(10) Determine the concentration of IgG using VH 1-69 germline gene in serum

[0047] Human IgG ELISA Quantitation set (Bethyl Laboratories, Inc) was used, with slight modification. K1-18 Ab for detection of IgG using VH 1-69 germline gene and affinity purified Human IgG coating antibody for standard curve were coated onto 96 well Maxisorp immunoplate. Serum and Human reference serum (for standard curve) was added to the assigned well. After incubation with HRP conjugated Human IgG Detection Antibody, TMB substrate was added to each well. Peroxidase reaction was stopped by adding H₂SO₄ and the absorbance of sample at 450nm was measured. The concentration of IgG bound to K1-18 Ab was calculated from standard curve of human reference serum.

(11) Virus-neutralizing activity of serum in the presence of K1-18 Ab

[0048] Virus neutralization test described above was modified. In brief, serum treated with RDE was diluted at 1:10 or 1:20 in serum-free medium and mixed with equal volume of 800 or 1,600 µg/ml of K1-18 Ab. After incubation, two-fold serial dilutions of the mixture were mixed with equal volume of 100 FFU of influenza virus, and applied to MDCK cells in 96 well plate. After incubation, the cells were fixed with ethanol and stained with PAP (peroxidase and anti-peroxidase) complex. The reciprocal of the highest dilution of serum to show 50% focus reduction rate was indicated as virus neutralizing activity.

2. Results

(1) Two types of virus-neutralizing Abs with different characteristics

[0049] We examined the total repertoire of Abs induced by vaccination with S-IOV. The blood donor in this study was born in 1947. He suffered from influenza several times in his childhood (possibly by H1N1 and H2N2) and finally in 1968 (probably by H3N2). During 41 years afterwards, he did not suffer from influenza at all, and moreover, he had never been vaccinated against influenza. The schedule of vaccination and blood collection was indicated in Fig. 4. This operation was performed for the period from the end of October until the middle of December in 2009 and the examinee did not

have an opportunity of natural infection with S-IOV. By using B lymphocytes collected before and after vaccination, two large Ab libraries were constructed and subjected to screenings by panning with pandemic H1N1 (A/California/2009pdm) and with seasonal H1N1 (A/Brisbane/2007) virus particles. After the second and the third rounds of panning with the viruses, 120 clones were isolated. The clones that bound to the H1N1 virus particle that had been used for screenings were further analyzed. The clones that bound to both H1N1 and H3N2 at equally intense strength were excluded since it is likely they are anti-NP Abs (Reference 8). Among 240 clones isolated in respective screenings, the number of clones that have been judged to be anti-HA Abs is as follows: screening 1 (library after vaccination, panning with pandemic virus), 105 clones; screening 2 (library before vaccination, panning with pandemic virus), 3 clones; screening 3 (library after vaccination, panning with seasonal virus), 58 clones; screening 4 (library before vaccination, panning with seasonal virus), 16 clones. V_H nucleotide sequences of all these clones were determined. Comparison of the amino acid sequences revealed that these 182 clones were composed of 96 unique monoclonal Abs (mAbs). Based on sequence similarities of V_H fragments, in particular the comparison of complementarity-determining region 3 (CDR3) sequences, the 96 clones were classified into 63 groups. The amino acid sequence of V_H fragment and the nucleotide sequence of CDR3 of all the clones are available in Fig. 5.

[0050] Using representative clones of the 63 groups, the following activities were examined: the binding activity to HAs; hemagglutination inhibition (HI) activity; the virus-neutralizing activity (Reference 9). As shown in Fig. 1, they were classified into two types without any exceptional clone. Clones classified into the first type bind only to the pandemic H1N1 not to the seasonal H1N1. All of them show HI activity. They were isolated only from screening 1. Clones classified into the second type bind not only to the pandemic H1N1 but also to all of the seasonal H1N1s. While they do not show HI activity, most of them neutralize not only H1N1 viruses but also H5N1 virus. Judging from low frequency of mutation such as 0 to 5 %, majority of the first type clones should be the products by B cells that have been newly induced through vaccination. On the other hand, all the clones except for few in the second type should correspond to the products by long-lived memory B cells that had been established before vaccination, judging from high frequency of mutation such as 10 to 15 %. Furthermore, they utilize 1-69 V_H gene except for three clones.

[0051] Of 105 clones isolated from screening 1, 98 were the first type and only 7 were the second type. Since the second type clones can bind to not only HA of the seasonal virus but also that of the pandemic virus, this low number means that the number of cells that produced the second type Abs was much lower than that of the first type Abs in the blood. As the first type Ab, 98 clones were isolated and classified into 31 groups. Of 31 groups, only one clone was isolated in 19 groups, and 2 clones were isolated in 7 groups. Similarly, as the second type Ab, 85 clones were isolated and classified into 32 groups. Of 32 groups, only one clone was isolated in 14 groups, and 2 clones were isolated in 8 groups. Taking account of the Poisson distribution, these observations suggested that there should be more clones that we have overlooked in this screening. However, it is unlikely that we have specifically overlooked the clones whose characteristics are very different from those listed in Fig. 1.

(2) Newly appearing Abs after vaccination

[0052] Since virtually all the first type Abs showed HI activity, it is likely that their epitopes are located in the surrounding region of a sialic acid-binding pocket. In order to systematically examine the relative position of the epitopes recognized by these clones we adopted the competition method which we had used in the previous study (Reference 10). While respective mAbs are initially prepared as Fab-cp3 form after the screening of libraries, they can be easily changed to Fab-PP (P denotes a single Fc-binding domain of protein A) form in our vector construct (Reference 11). If the epitope recognized by clone A is overlapped with that by clone B, the binding of Fab-PP form of clone A to HA is largely disturbed by the presence of a large amount of Fab-cp3 form of clone B. Based on this principle, the competition study was performed using 17 clones selected from the first type Abs listed in Fig. 1. As the results are shown in Fig. 2, 14 clones among 17 well competed against one another for the binding to HA. In the case of three clones, F082-317, F082-254 and F082-022, the degree of disturbance for the binding was low. These observations are consistent with other data. Only F082-022 showed very low HI activity (titer 160 μ g/ml). F082-254 binds to HA of not only pandemic virus but also seasonal virus and neutralizes both viruses. Furthermore, high frequency of mutation such as 18 % was observed in this clone. In the case of F082-317, the binding activity to HA is high but the neutralizing activity is relatively low.

[0053] Based on these observations we concluded that the sialic acid-binding pocket and its surrounding regions on HA are immunogenically very potent, and virtually all the B cells whose growth is newly induced and expanded by vaccination produce Abs that recognize these regions. In addition, when even formalin-treated virus particles that are not alive are used as vaccine, B cells producing Abs that are able to bind to HA but not able to neutralize virus are not induced at a substantial level. The second conclusion suggested that the non-neutralizing epitope on HA, even if it exists, is immunologically impotent.

(3) Abs encoded by long-lived memory B cells

[0054] While the second type clones are classified into 32 groups, they utilized 1-69 V_H gene except for three clones. Furthermore, majority of them are able to neutralize not only all of H1N1 viruses but also H5N1 virus. These observations suggested that the epitopes recognized by these clones should be closely located at that recognized by C179 as shown by several groups (References 12 and 13). Then, we examined whether the binding of C179 to HA is really disturbed by presence of large excess of Fab-cp3 form of these clones. As the results are shown in Fig. 3, all of the clones including three that did not utilize 1-69 V_H gene disturbed the binding of C 179 to HA. Thus, the second type clones should bind to the membrane-proximal stem of HA in the same or similar way as other Abs using 1-69 V_H gene (1-69Abs), such as CR6261 and F10, already described by other groups (References 12 and 13). Figure 3 also indicated that four clones, F081-268, F082-243, F082-237, and F083-373, showed weaker disturbance activity than the others. The data shown in Fig. 1 indicated that F081-268 showed intense HA-binding activity but the neutralizing activity was weak. The other three clones showed relatively weak binding and neutralizing activities. Thus, while all of the epitopes recognized by the second type Abs are not exactly the same as that by C179, we did not find any clone that binds to the epitope totally different from that recognized by C 179. This suggested that this epitope has been shared and stably kept among group 1 viruses. Even if the immunogenicity of this epitope is weak, once humans acquired B cells that produce Abs that recognize this epitope, they could have been kept in their bodies as memory cells for a long time and have become major players against group 1 viruses. Interestingly, one clone F083-115-1 that utilized 1-69 V_H gene is able to neutralize even H3N2 virus.

[0055] Eighty-four clones isolated as the second type Abs were composed of 49 unique clones. They were further classified into 32 groups. Although we assumed that respective groups may correspond to B cells that had been matured independently of one another during differentiation of B cells, some of the clones that were classified into different groups in Fig. 1 may have been derived from the same B cells. Even if this is the case, the list of clones summarized in Fig. 1 indicated that more than 10 B cells using 1-69 V_H gene had been independently established in the donor's body probably when he was young. While 16 anti HA clones were isolated from screening 4 (library before vaccination, panning with seasonal virus), there was no clone that binds to HA of seasonal H1N1 virus but not to that of pandemic virus. All of them were the second type Abs. Since the library used in this screening was constructed from B cells before vaccination, expansion of the first type B cells through vaccination did not give any influence on the characteristics of clones isolated from screening 4. If there were B cells that produce Abs that bind to the globular head of HA in seasonal H1N1 viruses at a substantial level, we should have obtained such clones. The strategy adopted in this study were utilized in analyses of repertoire of neutralizing Abs against H3N2 viruses in three blood donors in our previous study (References 8 and 10). Although vaccination step was not included in the previous study, most of the Abs isolated bound to the globular head of HA (References 10 and 14). Thus, we concluded that the 1-69Abs that are able to neutralize all of group 1 viruses should have been major players against group 1 influenza A viruses in the donor's body for a long time.

(4) Presence of Abs secreted into the serum

[0056] Two biological activities, HI activity and virus-neutralizing activity, against three viral strains, H1N1 pandemic virus, seasonal H1N1 virus and H5N1 virus, were measured using eight samples of sera collected from the examinee at different date as shown in Fig. 4.

[0057] As indicated in Fig. 6, in the case of HI, the activity against seasonal H1N1 and H5N1 viruses was not detected in all the sera. Against H1N1 pandemic virus, HI activity started to appear two weeks after the first vaccination. In the case of virus-neutralizing activity measured by standard focus reduction assay, the activity against H1N1 pandemic virus already started to increase one week after vaccination and reached to plateau two weeks after vaccination. Against seasonal H1N1 virus, virus-neutralizing activity was detected even before vaccination and increased one week after vaccination. Against H5N1 virus, virus-neutralizing activity was not detected by the standard focus-reduction assay (Reference 9) but detected by more sensitive method (Reference 15).

[0058] Since virus-neutralizing activity against H5N1 virus should be derived from the set of Abs which had been originally generated against H1N1 and probably H2N2 viruses in the examinee's body and were listed as the second type in Fig. 1, the difference observed between seasonal H1N1 virus and H5N1 virus may correspond to difference in the strength of activity, that is, the activity against seasonal H1N1 virus is several times intenseer than that against H5N1 virus. It should be noteworthy that virus-neutralizing activity against seasonal H1N1 was observed at the detectable level even before vaccination.

[0059] In order to prove that 1-69Abs are really responsible for neutralizing H1N1 pandemic virus, seasonal H1N1 virus and H5N1 virus, we decided to prepare mAb that can specifically bind to 1-69Abs, that is anti-idiotypic Ab, and hopefully inhibit the binding of 1-69Ab to HA. We expected that the region including two amino acids, isoleucine at the 53rd residue and phenylalanine at the 54th residue, in V_H domain should be immunogenic in mice since presence of two hydrophobic residues in CDR2 is very unique, and is found only in 1-69Ab of human (Reference 16). We expected

that an anti-idiotypic Ab is able to inhibit the binding of 1-69Ab to HA since it has been shown that these two amino acids are directly involved in the Ab/HA interaction (References 12 and 13). We isolated mAb K1-18 that can bind to more than 80 % of 1-69Abs listed in Fig. 1. For half of the 1-69Abs, the binding to HA is inhibited by K1-18. See "Methods and Fig. 8 for the details.

[0060] Using K1-18 as probe, amount of IgG form of 1-69Ab in serum was measured. The results indicated that it was present at the concentration of 4.58 $\mu\text{g/ml}$ in the serum of October 30 (before vaccination) and increased after vaccination to the concentration of 11.24 $\mu\text{g/ml}$ in the serum of December 14 (after vaccination). Virus-neutralizing activity against pandemic and seasonal H1N1 viruses were measured under presence of K1-18. In the case of H1N1 pandemic virus, K1-18 definitely inhibited the neutralizing activity as indicated in Fig. 7. Against seasonal H1N1 virus, the inhibition was clearly observed although not perfectly. Thus, we concluded that 1-69Abs were really present in the sera and functioned in neutralization of H1N1 viruses. Furthermore, the data in Fig. 7 suggested that when two types of functionally different Abs co-exist, the first type prevents HA/receptor interaction and the second type prevents low-pH-induced conformational change of HA, the virus-neutralizing activity synergistically increases.

3. Perspective

[0061] In the study reported before, the research group of the present inventors analyzed the neutralization antibody repertoires of three humans through isolation of large amounts of anti-HA antibodies against 12 kinds of different H3 strains that were isolated in a period from 1968 to 2004 (Reference Documents 8, 10 and 14). Most of the antibodies isolated from two donors who were born in 1960 and 1944 were classified into three groups having different strain specificities (specificities to strains in a period from 1968 to 1973, specificities to strains in a period from 1977 to 1993, and specificities to strains in a period from 1997 to 2003). Five sites of A, B, C, D and E that are positioned on the head part of HA were isolated as neutralizing epitopes, whereas many of the clones that neutralizes the strains in a period from 1977 to 1993 bonded to the site C. The clones that were isolated from the third donor born in 1974 can be classified into four types. Type 1 strongly bound to the 1973 strain, and the strain specificity was narrow. Type 2 bound to the HAs of the strains in a period from 1997 to 2003. The other two types were antibodies that broadly neutralize the strains. One was an antibody that neutralizes all kinds of H3N2, and the other was an antibody that neutralizes not only H3 but also group 1 viruses including H1, H2 and H5. After a set of B cells producing Abs that can neutralize the viruses are generated by immunization through infection and/or vaccination, they will take various courses under further stimulation with the antigens (Ags). Some B cells disappear but others remain as memory cells. Furthermore, there should be long-lived memory cells and short-lived memory cells. Humans who experience an outbreak of flu almost every year should have opportunities to be infected by novel influenza viruses that have drifted away from previous virus. Some memory cells produce Abs that are able to neutralize the novel viruses but others produce Abs that cannot neutralize them. They would be selected through presence or absence of stimulation with the Ags. According to this hypothesis the stability of the epitope would greatly affect the fate of memory B cells. The present study indicated that only the cells producing 1-69Abs which can neutralize all the group1 viruses remained as memory cells. In this experiment we analyzed the person who had experience of suffering from influenza disease in their youth but never suffered from this disease afterwards. Since the donor had not received any influenza vaccine until then, it is considered that the antibody repertoire produced in the body of the donor was produced by only an effect of infection with a living virus. An antibody repertoire that is formed in the body of a human that has received a vaccine many times with a formalin-treated virus would not indicate a simple tendency as shown in this study. Further, although only one person was analyzed in this study, it seemed likely that any human is able to generate 1-69Abs that can broadly neutralize group 1 viruses since only 1-69 V_H gene is required for producing a broadly neutralizing Ab without participation of V_L domain in forming the Ag-binding site, and furthermore, the requirements of CDR3 sequence in V_H for binding to HA stem appeared to be limited. While further experiments are required to examine whether Abs produced in the type 2 clones are intense enough for preventing infection with future pandemic caused by highly pathogenic avian influenza (HPAI) H5N1 virus, we may expect that presence of type 2 clones as memory cells could be helpful for preventing expansion of the pandemic viruses in their bodies. Thus, we propose that the strategy for protection against the H5N1 pandemic should be designed according to the immunological carrier of respective persons. Presence of anti HA Abs utilizing 1-69 V_H gene could be a useful indicator for the judgment and anti idiotypic Abs against 1-69Abs could be the reagent.

INDUSTRIAL APPLICABILITY

[0062] The present invention is useful as a countermeasure for handling a pandemic of a type A influenza virus. By utilizing the present invention, it becomes possible to take a reasonable and effective countermeasure for handling the pandemic.

[0063] The present invention will not be limited to the description of the embodiments and examples of the present invention. Various modifications readily made by those skilled in the art are also included in the present invention, without

departing from the scope of claims.

[0064] The contents of the articles, unexamined patent publications, and patent applications specified herein are hereby incorporated herein by reference.

References

[0065]

1. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Ann. Rev. Biochem.* 69, 531-569 (2000).
2. Knossow, M. et al. Mechanism of neutralization of influenza virus infectivity by antibodies. *Virology* 302, 294-298 (2002).
3. Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J. Virol.* 67, 2552-2558 (1993).
4. Fraser, C. et al. Pandemic potential of a strain of influenza A (H1N1): early findings. *Science* 324, 1557-1561 (2009).
5. Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.* 361, 1945-1952 (2009).
6. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med.* 208, 181-193 (2011).
7. Li, G.M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. *Proc. Natl. Acad. Sci.* 109, 9047-9052 (2012).
8. Okada, J. et al. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified in to three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. *Virology* 397, 322-330 (2010).
9. Okuno, Y. et al. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. *J. Clin. Microbiol.* 28, 1308-1313 (1990).
10. Ohshima, N. et al. Naturally occurring antibodies in humans can neutralize a variety of influenza viral strains, including H3, H1, H2, and H5. *J. Virol.* 85, 11048-11057 (2011).
11. Ito, W. & Kurosawa, Y. Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A. *J. Biol. Chem.* 268, 20668-20675 (1993).
12. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nat. Struct. Mol. Biol.* 16, 265-273 (2009).
13. Ekiert, D.C. et al. Antibody recognition of a highly conserved influenza virus epitope. *Science* 324, 246-251 (2009).
14. Okada, J. et al. Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. *J. Gen. Virol.* 92, 326-335 (2011).

[Sequence list free text]

[0066]

SEQ ID NO:129: explanation of artificial sequence: primer T7ETZ

EP 3 037 819 A1

SEQUENCE LISTING

<110> FUJITA HEALTH UNIVERSITY
 5 <120> DETERMINATION METHOD FOR RESISTANCE TO INFLUENZA VIRUS
 <130> CT12002P
 <150> JP P2013-172902
 10 <151> 2013-08-23
 <160> 129
 <170> PatentIn version 3.5
 15 <210> 1
 <211> 17
 <212> PRT
 <213> Homo sapience
 <400> 1
 20 Asp Thr Thr Val Thr Asn Glu Glu Ile Asn Phe Tyr Tyr Gly Met Asp
 1 5 10 15
 Val
 25
 <210> 2
 <211> 17
 30 <212> PRT
 <213> Homo sapience
 <400> 2
 35 Asp Thr Glu Val Thr Asn Glu Glu Ile Asn Phe Tyr Tyr Gly Met Asp
 1 5 10 15
 Val
 40
 <210> 3
 <211> 17
 <212> PRT
 45 <213> Homo sapience
 <400> 3
 50 Asp Thr Glu Val Thr Ser Glu Glu Ile Asn Phe Tyr Tyr Gly Met Asp
 1 5 10 15
 Val
 55
 <210> 4
 <211> 17
 <212> PRT

EP 3 037 819 A1

<213> Homo sapience

<400> 4

5 Asp Thr Thr Val Thr Ser Glu Glu Ile Asn Phe Tyr Gln Gly Met Asp
1 5 10 15

Val

10

<210> 5

<211> 17

<212> PRT

15

<213> Homo sapience

<400> 5

20

Glu Phe Gly Ala Asn Gly Glu Asp Ile Tyr Phe Tyr His Gly Met Asp
1 5 10 15

Val

25

<210> 6

<211> 19

<212> PRT

<213> Homo sapience

30

<400> 6

Ser Ile Gly Gly Tyr Asp Gly Glu Gly Ile Phe Tyr Asn His Tyr Gly
1 5 10 15

35

Met Asp Val

40

<210> 7

<211> 14

<212> PRT

<213> Homo sapience

<400> 7

45

Asp Glu Trp Phe Gly Glu Leu Gly Ser Ser Gly Met Asp Val
1 5 10

50

<210> 8

<211> 14

<212> PRT

<213> Homo sapience

<400> 8

55

Asp Phe Ala Gly Glu Gly His Gly Ser Gly Ser Val Asp Tyr
1 5 10

EP 3 037 819 A1

<210> 9
 <211> 20
 <212> PRT
 <213> Homo sapience
 5
 <400> 9
 Ser Ala Thr Ser Tyr Arg Asp Tyr Leu Asp Arg Asp Phe Phe Tyr Tyr
 1 5 10 15
 10
 Ala Leu Asp Val
 20
 15
 <210> 10
 <211> 20
 <212> PRT
 <213> Homo sapience
 20
 <400> 10
 Ser Ala Thr Ser Tyr Arg Asp Tyr Leu Asp Arg Asp Phe Tyr Tyr Tyr
 1 5 10 15
 25
 Ala Leu Asp Val
 20
 30
 <210> 11
 <211> 17
 <212> PRT
 <213> Homo sapience
 <400> 11
 35
 Asp His Leu Asn Ser Glu Ile Val Ala Thr Ile Thr Gly Phe Leu Asp
 1 5 10 15
 Tyr
 40
 <210> 12
 <211> 17
 <212> PRT
 <213> Homo sapience
 45
 <400> 12
 Asp Lys Leu Asn Ser Glu Met Val Ala Thr Ile Thr Gly Phe Leu Asp
 1 5 10 15
 50
 Tyr
 55
 <210> 13
 <211> 17

EP 3 037 819 A1

<212> PRT
<213> Homo sapience

<400> 13

5
Asp Lys Leu Asn Ser Glu Met Val Ala Thr Ile Thr Gly Phe Met Asp
1 5 10 15

Tyr

10

<210> 14
<211> 17
<212> PRT
<213> Homo sapience

15

<400> 14

20
Asp Lys Leu Asn Ser Asp Glu Val Thr Thr Ile Thr Gly Phe Leu Asp
1 5 10 15

Tyr

25

<210> 15
<211> 17
<212> PRT
<213> Homo sapience

30

<400> 15

35
Asp Asn Leu Asn Ser Glu Leu Val Ala Thr Ile Thr Gly Phe Leu Asp
1 5 10 15

35

His

40

<210> 16
<211> 17
<212> PRT
<213> Homo sapience

45

<400> 16

Asp Asn Leu Asn Ser Asp Glu Val Ala Thr Ile Ser Gly Phe Leu Asp
1 5 10 15

50

Tyr

55

<210> 17
<211> 17
<212> PRT
<213> Homo sapience

EP 3 037 819 A1

<400> 17

Asp Tyr Leu Asn Ser Glu Met Val Ala Thr Ile Thr Gly Phe Leu Asp
1 5 10 15

Ser

<210> 18

<211> 17

<212> PRT

<213> Homo sapience

<400> 18

Glu Pro Ser Asn Thr Glu Asp Ile Arg Gly Ile Glu Gly Val Phe Asp
1 5 10 15

Tyr

<210> 19

<211> 15

<212> PRT

<213> Homo sapience

<400> 19

Asp Ala Tyr Ser Ser Gly Asp Thr Tyr Tyr Tyr Gly Leu Asp Val
1 5 10 15

<210> 20

<211> 17

<212> PRT

<213> Homo sapience

<400> 20

Asp Arg Gly Thr Gly Glu Gln Ile Ala Val Val Thr Ala Leu Ile Asp
1 5 10 15

Tyr

<210> 21

<211> 12

<212> PRT

<213> Homo sapience

<400> 21

His Gly Tyr Gly Asp Tyr Val Gly Tyr Phe Asp Tyr
1 5 10

<210> 22

EP 3 037 819 A1

<211> 15
 <212> PRT
 <213> Homo sapience

 5 <400> 22

 Val Leu Arg Trp Leu Gly Glu Glu Asp Ala Asp Ala Phe Asp Ile
 1 5 10 15

 10 <210> 23
 <211> 18
 <212> PRT
 <213> Homo sapience

 15 <400> 23

 Gly Phe Gly Met Val Gly Asp Thr Val Asp Asp Leu Tyr Asn Gly Met
 1 5 10 15

 20 Asp Val

 25 <210> 24
 <211> 15
 <212> PRT
 <213> Homo sapience

 <400> 24

 30 Val Gln Arg Pro Tyr Gly Asp Tyr Ala Ala Gly Ala Phe Asp Ile
 1 5 10 15

 35 <210> 25
 <211> 15
 <212> PRT
 <213> Homo sapience

 <400> 25

 40 Val Gln Arg Pro Tyr Gly Asp Tyr Ile Thr Gly Ala Phe Asp Ile
 1 5 10 15

 45 <210> 26
 <211> 19
 <212> PRT
 <213> Homo sapience

 <400> 26

 50 Arg Thr Trp Tyr Tyr Asp Gly Ser Gly Pro Asp Pro Ser Arg Asp Ala
 1 5 10 15

 Phe Asp Ile

 55 <210> 27

EP 3 037 819 A1

<211> 19
<212> PRT
<213> Homo sapience

5

<400> 27

Asp Leu Gly Asn Gly Glu Asp Ile Ala Val Gln Pro Gly Thr Ile Gly
1 5 10 15

10

Val Asp Tyr

<210> 28
<211> 19
<212> PRT
<213> Homo sapience

15

<400> 28

20

Asp Leu Gly Asn Gly Glu Asp Ile Ala Val Gln Pro Gly Thr Thr Gly
1 5 10 15

Val Asp Tyr

25

<210> 29
<211> 19
<212> PRT
<213> Homo sapience

30

<400> 29

Asp Leu Gly Asn Gly Glu Asp Ile Val Val Gln Pro Ala Thr Ile Gly
1 5 10 15

35

Val Asp Tyr

40

<210> 30
<211> 17
<212> PRT
<213> Homo sapience

45

<400> 30

Gly Thr Glu Val Thr Thr Glu Glu Ile Tyr Phe Tyr Tyr Gly Met Asp
1 5 10 15

50

Val

<210> 31
<211> 17
<212> PRT
<213> Homo sapience

55

EP 3 037 819 A1

<400> 31

Gly Thr Glu Val Thr Thr Glu Glu Ile Asn Phe Tyr Tyr Gly Met Asp
1 5 10 15

Val

<210> 32

<211> 16

<212> PRT

<213> Homo sapience

<400> 32

Ala Glu Lys Trp Leu Ala Asp Tyr Phe Tyr Tyr Phe Gly Met Asp Val
1 5 10 15

<210> 33

<211> 20

<212> PRT

<213> Homo sapience

<400> 33

Asp Arg Glu Glu Ser Leu Phe Ala Gly Ala Ile Tyr Asn Tyr Tyr Tyr
1 5 10 15

Asp Met Asp Val
20

<210> 34

<211> 18

<212> PRT

<213> Homo sapience

<400> 34

Lys Gly Gly Ala Lys Leu Leu Tyr Phe Asp Trp Leu Ala Ser Ala Phe
1 5 10 15

Asp Ile

<210> 35

<211> 11

<212> PRT

<213> Homo sapience

<400> 35

Gly Pro Asn Tyr Tyr Glu Asn Phe Phe Asp Tyr
1 5 10

EP 3 037 819 A1

5
 <210> 36
 <211> 11
 <212> PRT
 <213> Homo sapience
 <400> 36
 Gly Pro Asn Tyr Tyr Glu Ser Tyr Phe Asp Tyr
 1 5 10
 10
 <210> 37
 <211> 11
 <212> PRT
 <213> Homo sapience
 15
 <400> 37
 Gly Pro Asn Tyr Tyr Glu Asn Tyr Phe Asp Phe
 1 5 10
 20
 <210> 38
 <211> 11
 <212> PRT
 <213> Homo sapience
 25
 <400> 38
 Gly Pro Asn Tyr Tyr Glu Ser Tyr Leu Asp Phe
 1 5 10
 30
 <210> 39
 <211> 11
 <212> PRT
 <213> Homo sapience
 35
 <400> 39
 Gly Pro Asn Tyr Phe Glu Ser Tyr Phe Asp Asn
 1 5 10
 40
 <210> 40
 <211> 11
 <212> PRT
 <213> Homo sapience
 45
 <400> 40
 Gly Pro Asn Tyr Tyr Glu Thr Tyr Leu Asp Asn
 1 5 10
 50
 <210> 41
 <211> 11
 <212> PRT
 <213> Homo sapience
 55
 <400> 41
 Gly Pro His Tyr Tyr Glu Ser His Leu Asp Tyr

EP 3 037 819 A1

1 5 10

5

<210> 42
<211> 11
<212> PRT
<213> Homo sapience

<400> 42

10

Gly Pro His Tyr Tyr Val Ser Tyr Phe Asp Ser
1 5 10

15

<210> 43
<211> 11
<212> PRT
<213> Homo sapience

<400> 43

20

Gly Asn Thr Tyr Tyr Ser Ser Tyr Phe Asp Gln
1 5 10

25

<210> 44
<211> 11
<212> PRT
<213> Homo sapience

<400> 44

30

Gly Ser Thr Tyr Tyr Ser Ser Tyr Phe Asp Gln
1 5 10

35

<210> 45
<211> 11
<212> PRT
<213> Homo sapience

<400> 45

40

Ser Gly Thr Tyr Tyr Val Ser Tyr Phe Asp Ser
1 5 10

45

<210> 46
<211> 11
<212> PRT
<213> Homo sapience

<400> 46

50

Ser Gly Thr Tyr Tyr Val Ser Tyr Leu Asp Ser
1 5 10

55

<210> 47
<211> 11
<212> PRT
<213> Homo sapience

EP 3 037 819 A1

<400> 47

Ser Gly Thr Tyr Tyr Val Ser Phe Phe Asp Tyr
1 5 10

<210> 48

<211> 11

<212> PRT

<213> Homo sapience

<400> 48

Ser Gly Ser Tyr Tyr Pro Asp Tyr Phe Gln Tyr
1 5 10

<210> 49

<211> 11

<212> PRT

<213> Homo sapience

<400> 49

Ser Pro Thr Tyr Tyr Pro Gly Ala Leu Asp Met
1 5 10

<210> 50

<211> 11

<212> PRT

<213> Homo sapience

<400> 50

Ala Pro Leu Ile Tyr Asn Trp Tyr Phe Asp Leu
1 5 10

<210> 51

<211> 11

<212> PRT

<213> Homo sapience

<400> 51

Ala Pro Leu Ile Tyr Asn Trp Tyr Tyr Asp Leu
1 5 10

<210> 52

<211> 12

<212> PRT

<213> Homo sapience

<400> 52

His Pro Thr Tyr His Tyr Gly Ser Ala Met Asp Tyr
1 5 10

<210> 53

<211> 12

EP 3 037 819 A1

<212> PRT
 <213> Homo sapience
 <400> 53

5

His Pro Thr Tyr Tyr Phe Gly Ser Ala Met Glu Tyr
 1 5 10

10

<210> 54
 <211> 12
 <212> PRT
 <213> Homo sapience
 <400> 54

15

His Pro Thr Tyr Tyr Tyr Gly Ser Pro Met Asp Tyr
 1 5 10

20

<210> 55
 <211> 12
 <212> PRT
 <213> Homo sapience
 <400> 55

25

His Pro Met Tyr His Tyr Gly Ser Ala Met Asp Tyr
 1 5 10

30

<210> 56
 <211> 12
 <212> PRT
 <213> Homo sapience
 <400> 56

35

His Ser Gly Tyr His Leu Ile Gly Tyr Phe Asp Ser
 1 5 10

40

<210> 57
 <211> 13
 <212> PRT
 <213> Homo sapience
 <400> 57

45

Glu Glu Gly Tyr Tyr Tyr Gly Ser Gly Pro Leu Asp Ser
 1 5 10

50

<210> 58
 <211> 13
 <212> PRT
 <213> Homo sapience
 <400> 58

55

Asn Ser Gly Tyr His Ile Ser Gly Phe Tyr Leu Asp Tyr
 1 5 10

EP 3 037 819 A1

<210> 59
 <211> 13
 <212> PRT
 <213> Homo sapience

<400> 59

Ser Leu Gly Tyr His Thr Gln Tyr Asn Gly Met Asp Val
 1 5 10

<210> 60
 <211> 15
 <212> PRT
 <213> Homo sapience

<400> 60

His Pro Thr Tyr His Phe Asp Lys Ser Gly Tyr Arg Phe Asp Ser
 1 5 10 15

<210> 61
 <211> 15
 <212> PRT
 <213> Homo sapience

<400> 61

Ser Arg Gly Tyr Ser Phe Gly Tyr Gly Thr Asp Tyr Phe Asp Tyr
 1 5 10 15

<210> 62
 <211> 15
 <212> PRT
 <213> Homo sapience

<400> 62

Asn Tyr Tyr Gly Ser Gly Thr Tyr Phe Asn Asp Ala Phe Asp Ile
 1 5 10 15

<210> 63
 <211> 14
 <212> PRT
 <213> Homo sapience

<400> 63

Tyr Gln Ser Ser Asp Tyr Tyr Asn Ser Glu Tyr Phe Gln His
 1 5 10

<210> 64
 <211> 126
 <212> PRT
 <213> Homo sapience

<400> 64

EP 3 037 819 A1

	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ser	Glu	Val	Lys	Lys	Pro	Gly	Ala	
	1				5					10					15		
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Asn	
				20					25					30			
10	Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
15	Gly	Trp	Ile	Ser	Gly	Leu	Asn	Gly	Asn	Thr	Asn	Tyr	Ala	Gln	Lys	Leu	
	50						55					60					
20	Gln	Gly	Arg	Val	Thr	Met	Thr	Thr	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr	
	65					70					75					80	
25	Met	Glu	Leu	Arg	Ser	Leu	Thr	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Phe	Cys	
					85					90					95		
30	Ala	Arg	Asp	Thr	Thr	Val	Thr	Asn	Glu	Glu	Ile	Asn	Phe	Tyr	Tyr	Gly	
				100					105					110			
35	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser			
			115					120					125				
40	<210>	65															
	<211>	126															
	<212>	PRT															
	<213>	Homo sapience															
45	<400>	65															
50	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Met	Lys	Lys	Pro	Gly	Ala	
	1				5					10					15		
55	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr	
				20					25					30			
60	Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
65	Gly	Trp	Ile	Ser	Ala	Asn	Asn	Gly	Asn	Thr	Asn	Tyr	Ala	Gln	Lys	Leu	
	50						55					60					
70	Gln	Gly	Arg	Val	Thr	Met	Thr	Thr	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr	
	65					70					75					80	
75	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		

EP 3 037 819 A1

Ala Arg Asp Thr Glu Val Thr Asn Glu Glu Ile Asn Phe Tyr Tyr Gly
100 105 110

5 Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125

10 <210> 66
<211> 126
<212> PRT
<213> Homo sapience

<400> 66

15 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Met Lys Lys Pro Gly Ala
1 5 10 15

20 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25 Gly Trp Ile Ser Ala Asn Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60

30 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

35 Ala Arg Asp Thr Glu Val Thr Ser Glu Glu Ile Asn Phe Tyr Tyr Gly
100 105 110

40 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

45 <210> 67
<211> 126
<212> PRT
<213> Homo sapience

<400> 67

50 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

55 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met

EP 3 037 819 A1

55

EP 3 037 819 A1

<211> 129
<212> PRT
<213> Homo sapience

5

<400> 69

Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln
1 5 10 15

10

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30

15

Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Leu Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Ser Pro Ser
50 55 60

20

Leu Lys Ser Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

25

Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala His Ser Ile Gly Gly Tyr Asp Gly Glu Gly Ile Phe Tyr Asn
100 105 110

30

His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
115 120 125

35

Ser

<210> 70
<211> 123
<212> PRT
<213> Homo sapience

40

<400> 70

45

Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Pro Gly Gly
1 5 10 15

50

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

55

Ala Asn Ile Glu Gln Asp Gly Ser Glu Lys Phe Tyr Val Asp Ser Val
50 55 60

EP 3 037 819 A1

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80

5 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

10 Ala Arg Asp Glu Trp Phe Gly Glu Leu Gly Ser Ser Gly Met Asp Val
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

15
<210> 71
<211> 123
<212> PRT
<213> Homo sapience

20 <400> 71

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Arg
1 5 10 15

25 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30

30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

35 Ser Gly Ile Ser Trp His Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Ser Leu Tyr
65 70 75 80

40 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

45 Ala Lys Asp Phe Ala Gly Glu Gly His Gly Ser Gly Ser Val Asp Tyr
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

50
<210> 72
<211> 129
<212> PRT
<213> Homo sapience

55 <400> 72

EP 3 037 819 A1

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Pro	Val	Lys	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Ala	Phe	Thr	Phe	Arg	Thr	Tyr	
				20					25					30			
10	Asp	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ser	Gly	Ile	Ser	Ser	Ser	Gly	Asp	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	
		50					55					60					
20	Gln	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	
25	Leu	Gln	Leu	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Phe	Cys	
				85						90					95		
30	Ala	Lys	Ser	Ala	Thr	Ser	Tyr	Arg	Asp	Tyr	Leu	Asp	Arg	Asp	Phe	Phe	
				100					105					110			
35	Tyr	Tyr	Ala	Leu	Asp	Val	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	
			115					120					125				
40	Ser																
45	<210>	73															
	<211>	129															
	<212>	PRT															
	<213>	Homo sapience															
50	<400>	73															
	Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Ser	Gly	Gly	
	1				5					10					15		
55	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Ala	Phe	Thr	Phe	Arg	Thr	Tyr	
				20					25					30			
60	Asp	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
65	Ser	Gly	Ile	Ser	Ser	Ser	Gly	Asp	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	
		50					55					60					
70	Gln	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	

EP 3 037 819 A1

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95

5 Ala Lys Ser Ala Thr Ser Tyr Arg Asp Tyr Leu Asp Arg Asp Phe Tyr
100 105 110

10 Tyr Tyr Ala Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
115 120 125

Ser

15

<210> 74
<211> 126
<212> PRT
<213> Homo sapience

20

<400> 74

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

25

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

30

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

35

Ala Val Met Ser Asp Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

40

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

45

Ala Arg Asp His Leu Asn Ser Glu Ile Val Ala Thr Ile Thr Gly Phe
100 105 110

Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

50

<210> 75
<211> 126
<212> PRT
<213> Homo sapience

55

<400> 75

EP 3 037 819 A1

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
10	Val	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ala	Val	Ile	Ser	Asp	Asp	Gly	Ile	Tyr	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	
		50					55					60					
20	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70				75					80		
25	Leu	Gln	Met	Asn	Ser	Leu	Arg	Gly	Glu	Asp	Thr	Thr	Val	Tyr	Tyr	Cys	
				85						90					95		
30	Ala	Arg	Asp	Lys	Leu	Asn	Ser	Glu	Met	Val	Ala	Thr	Ile	Thr	Gly	Phe	
				100					105					110			
35	Leu	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser			
			115					120					125				
40	<210>	76															
	<211>	126															
	<212>	PRT															
	<213>	Homo sapience															
45	<400>	76															
50	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	
	1				5					10					15		
55	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
60	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
65	Ala	Ile	Ile	Ser	Asp	Asp	Gly	Thr	His	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	
		50					55					60					
70	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70				75					80		
75	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Leu	Tyr	Tyr	Cys	
				85						90					95		

EP 3 037 819 A1

	Ala	Arg	Asp	Lys	Leu	Asn	Ser	Glu	Met	Val	Ala	Thr	Ile	Thr	Gly	Phe
				100					105					110		
5	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser		
			115					120					125			
10	<210>	77														
	<211>	126														
	<212>	PRT														
	<213>	Homo sapience														
	<400>	77														
15	Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
	1			5						10					15	
20	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
	Gly	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
			35					40					45			
25	Ala	Val	Ile	Ser	Asn	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val
		50					55					60				
30	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Met	Tyr
	65					70					75				80	
	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	His	Cys
				85						90					95	
35	Gly	Arg	Asp	Lys	Leu	Asn	Ser	Asp	Glu	Val	Thr	Thr	Ile	Thr	Gly	Phe
				100					105					110		
40	Leu	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser		
			115					120					125			
45	<210>	78														
	<211>	126														
	<212>	PRT														
	<213>	Homo sapience														
	<400>	78														
50	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
	1			5						10					15	
	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Val	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
				20					25					30		
55	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val

EP 3 037 819 A1

	35		40		45												
5	Ala	Val	Val	Ser	Asp	Asp	Glu	Ser	Tyr	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	
	50						55						60				
10	Lys	Gly	Arg	Phe	Ile	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70					75				80		
15	Leu	Gln	Ile	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Ser	Cys	
				85						90					95		
20	Ala	Arg	Asp	Asn	Leu	Asn	Ser	Glu	Leu	Val	Ala	Thr	Ile	Thr	Gly	Phe	
				100					105					110			
25	Leu	Asp	His	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser			
			115					120						125			
30	<210>	79															
	<211>	126															
	<212>	PRT															
	<213>	Homo sapience															
35	<400>	79															
	Gln	Val	Gln	Leu	Gln	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	
	1				5					10					15		
40	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
				20					25					30			
45	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
50	Ala	Val	Ile	Ser	Asn	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	
	50						55					60					
55	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	
	65					70					75				80		
60	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85						90					95		
65	Gly	Arg	Asp	Asn	Leu	Asn	Ser	Asp	Glu	Val	Ala	Thr	Ile	Ser	Gly	Phe	
				100					105					110			
70	Leu	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser			
			115					120						125			
75	<210>	80															

EP 3 037 819 A1

<211> 126
<212> PRT
<213> Homo sapience

5

<400> 80

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

10

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30

15

Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Leu Ile Ser Ser Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

20

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

25

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Tyr Leu Asn Ser Glu Met Val Ala Thr Ile Thr Gly Phe
100 105 110

30

Leu Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

35

<210> 81
<211> 126
<212> PRT
<213> Homo sapience

40

<400> 81

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

45

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30

Ala Val His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

50

Ala Asp Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60

55

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Met Leu Tyr
65 70 75 80

EP 3 037 819 A1

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 5
 Ala Thr Glu Pro Ser Asn Thr Glu Asp Ile Arg Gly Ile Glu Gly Val
 100 105 110
 10
 Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125
 15
 <210> 82
 <211> 124
 <212> PRT
 <213> Homo sapience
 <400> 82
 20
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 25
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Gln Tyr
 20 25 30
 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 35
 Ala Leu Ile Tyr Tyr Gly Gly Asn Pro Lys Ser Tyr Ala Asp Ser Val
 50 55 60
 40
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Ser
 65 70 75 80
 45
 Leu Glu Met Asn Asn Leu Arg Thr Glu Asp Thr Ala Ile Tyr Tyr Cys
 85 90 95
 50
 Ala Arg Asp Ala Tyr Ser Ser Gly Asp Thr Tyr Tyr Tyr Gly Leu Asp
 100 105 110
 55
 Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 115 120
 50
 <210> 83
 <211> 126
 <212> PRT
 <213> Homo sapience
 <400> 83
 55
 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
 1 5 10 15

EP 3 037 819 A1

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
20 25 30

5 Ala Met His Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

10 Ser Val Ile Asp Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Ser Leu Tyr
65 70 75 80

15 Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

20 Ala Lys Asp Arg Gly Thr Gly Glu Gln Ile Ala Val Val Thr Ala Leu
100 105 110

Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

25

<210> 84
<211> 122
<212> PRT
<213> Homo sapience

30

<400> 84

Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

35

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Asp
20 25 30

40

Ser Tyr Tyr Trp Asp Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

45

Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Ser Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

50

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

55

Cys Ala Arg His Gly Tyr Gly Asp Tyr Val Gly Tyr Phe Asp Tyr Trp
100 105 110

EP 3 037 819 A1

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

5
<210> 85
<211> 123
<212> PRT
<213> Homo sapience

10
<400> 85

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser His
20 25 30

20
Tyr Trp Ser Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

25
Gly Tyr Ile Tyr Tyr Gly Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

30
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

35
Arg Val Leu Arg Trp Leu Gly Glu Glu Asp Ala Asp Ala Phe Asp Ile
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

40
<210> 86
<211> 126
<212> PRT
45
<213> Homo sapience

<400> 86

Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

50
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Met Thr Thr His
20 25 30

55
Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Ile
35 40 45

EP 3 037 819 A1

	Gly	Asn	Ile	Tyr	Tyr	Ser	Gly	Gly	Thr	Glu	Tyr	Asn	Pro	Ser	Leu	Gln
	50						55					60				
5	Ser	Arg	Leu	Thr	Ile	Ser	Leu	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser	Leu
	65					70					75					80
	Thr	Leu	Thr	Ser	Gly	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
10					85					90					95	
	Arg	Gly	Phe	Gly	Met	Val	Gly	Asp	Thr	Val	Asp	Asp	Leu	Tyr	Asn	Gly
				100					105					110		
15	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser		
			115					120					125			
20	<210>	87														
	<211>	123														
	<212>	PRT														
	<213>	Homo sapience														
	<400>	87														
25	Glu	Val	Gln	Leu	Val	Glu	Ser	Val	Pro	Gly	Leu	Val	Lys	Pro	Ser	Glu
	1				5					10					15	
	Thr	Leu	Ser	Leu	Thr	Cys	Thr	Val	Ser	Gly	Gly	Ser	Ile	Ser	Thr	Tyr
30				20					25					30		
	Tyr	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile
			35					40					45			
35	Gly	Tyr	Ile	Tyr	Tyr	Ser	Gly	Ser	Thr	Asn	Tyr	Asn	Pro	Ser	Leu	Lys
	50						55					60				
	Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser	Leu
40	65					70					75					80
	Lys	Leu	Arg	Ser	Val	Thr	Ala	Ala	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala
45					85					90					95	
	Arg	Val	Gln	Arg	Pro	Tyr	Gly	Asp	Tyr	Ala	Ala	Gly	Ala	Phe	Asp	Ile
			100						105					110		
50	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser					
			115					120								
55	<210>	88														
	<211>	123														
	<212>	PRT														
	<213>	Homo sapience														

EP 3 037 819 A1

<400> 88

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Thr Tyr
20 25 30

Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Tyr Ile Asp Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Ile Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Arg Val Gln Arg Pro Tyr Gly Asp Tyr Ile Thr Gly Ala Phe Asp Ile
100 105 110

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 89

<211> 128

<212> PRT

<213> Homo sapience

<400> 89

Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Tyr
20 25 30

Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
50 55 60

Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80

Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Gly Met Tyr Tyr Cys

EP 3 037 819 A1

	85	90	95
5	Ala Arg Arg Thr Trp Tyr Tyr Asp Gly Ser Gly Pro Asp Pro Ser Arg 100 105 110		
10	Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125		
15	<210> 90 <211> 128 <212> PRT <213> Homo sapience <400> 90		
20	Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15		
25	Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30		
30	Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45		
35	Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe 50 55 60		
40	Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr 65 70 75 80		
45	Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95		
50	Ala Arg Asp Leu Gly Asn Gly Glu Asp Ile Ala Val Gln Pro Gly Thr 100 105 110		
55	Ile Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125		
	<210> 91 <211> 128 <212> PRT <213> Homo sapience <400> 91		
	Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala 1 5 10 15		
	Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30		

EP 3 037 819 A1

Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

5 Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe
50 55 60

10 Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr
65 70 75 80

15 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Leu Gly Asn Gly Glu Asp Ile Ala Val Gln Pro Gly Thr
100 105 110

20 Thr Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

25 <210> 92
<211> 128
<212> PRT
<213> Homo sapience

<400> 92

30 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
1 5 10 15

35 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30

Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

40 Gly Trp Val Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe
50 55 60

45 Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr
65 70 75 80

50 Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Leu Gly Asn Gly Glu Asp Ile Val Val Gln Pro Ala Thr
100 105 110

55 Ile Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

EP 3 037 819 A1

<210> 93
 <211> 126
 <212> PRT
 <213> Homo sapience

<400> 93

Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
 20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe
 50 55 60

Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr
 65 70 75 80

Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Ser Gly Thr Glu Val Thr Thr Glu Glu Ile Tyr Phe Tyr Tyr Gly
 100 105 110

Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 115 120 125

<210> 94
 <211> 126
 <212> PRT
 <213> Homo sapience

<400> 94

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Arg Tyr Ala Gln Gly Phe
 50 55 60

EP 3 037 819 A1

	Thr	Gly	Arg	Phe	Val	Phe	Ser	Leu	Asp	Thr	Ser	Val	Ser	Thr	Ala	Tyr	65	70	75	80
5	Leu	Gln	Ile	Ser	Ser	Leu	Lys	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys		85	90	95
10	Ala	Arg	Gly	Thr	Glu	Val	Thr	Thr	Glu	Glu	Ile	Asn	Phe	Tyr	Tyr	Gly		100	105	110
15	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser				115	120	125
	<210> 95																			
	<211> 125																			
	<212> PRT																			
	<213> Homo sapience																			
20	<400> 95																			
25	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala	1	5	10	15
30	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ile	Phe	Asn	Ser	Tyr		20	25	30
35	Ala	Ile	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Arg	Pro	Glu	Trp	Met		35	40	45
	Gly	Trp	Ile	Asn	Ile	Gly	Asn	Gly	Asn	Thr	Lys	Tyr	Ser	Gln	Lys	Phe		50	55	60
40	Gln	Gly	Arg	Val	Ala	Ile	Thr	Arg	Asp	Arg	Ser	Ala	Ser	Thr	Ala	Tyr	65	70	75	80
45	Met	Glu	Val	Thr	Ser	Leu	Arg	Phe	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys		85	90	95
	Ala	Thr	Ala	Glu	Lys	Trp	Leu	Ala	Asp	Tyr	Phe	Tyr	Tyr	Phe	Gly	Met		100	105	110
50	Asp	Val	Trp	Gly	Arg	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser					115	120	125
55	<210> 96																			
	<211> 129																			
	<212> PRT																			
	<213> Homo sapience																			
	<400> 96																			

EP 3 037 819 A1

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala	
	1				5					10					15		
5	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Ser	Ala	Tyr	
				20					25					30			
10	Tyr	Ile	His	Trp	Val	Arg	Gln	Ser	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
15	Gly	Val	Ile	Asn	Pro	Ser	Gly	Gly	Asp	Thr	Asn	Tyr	Ala	Gln	Arg	Phe	
		50					55					60					
20	Gln	Gly	Arg	Leu	Thr	Met	Thr	Arg	Asp	Thr	Ser	Thr	Ser	Thr	Val	Tyr	
	65					70					75					80	
25	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
30	Ala	Arg	Asp	Arg	Glu	Glu	Ser	Leu	Phe	Ala	Gly	Ala	Ile	Tyr	Asn	Tyr	
				100					105					110			
35	Tyr	Tyr	Asp	Met	Asp	Val	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	
			115					120					125				
40	Ser																
45	<210>	97															
	<211>	126															
	<212>	PRT															
	<213>	Homo sapience															
50	<400>	97															
55	Gln	Val	Gln	Leu	Gln	Gln	Trp	Gly	Ala	Gly	Leu	Leu	Lys	Pro	Ser	Glu	
	1				5					10					15		
60	Thr	Leu	Ser	Leu	Thr	Cys	Ala	Val	Tyr	Gly	Gly	Ser	Phe	Ser	Gly	Tyr	
				20					25					30			
65	Tyr	Trp	Ser	Trp	Ile	Arg	Gln	Pro	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile	
			35					40					45				
70	Gly	Glu	Ile	Asn	His	Ser	Gly	Ser	Thr	Lys	Asn	Asn	Pro	Ser	Leu	Lys	
		50					55					60					
75	Ser	Arg	Val	Thr	Ile	Ser	Val	Asp	Thr	Ser	Lys	Asn	Gln	Phe	Ser	Leu	
	65					70					75					80	

EP 3 037 819 A1

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95
 5 Arg Lys Gly Gly Ala Lys Leu Leu Tyr Phe Asp Trp Leu Ala Ser Ala
 100 105 110
 Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125
 10
 <210> 98
 <211> 120
 <212> PRT
 <213> Homo sapience
 15
 <400> 98
 Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 20 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Arg Asn
 20 25 30
 25 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Ile Ile Ala Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
 50 55 60
 30 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr
 65 70 75 80
 35 Met Glu Leu Ser Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 40 Ala Arg Gly Pro Asn Tyr Tyr Glu Asn Phe Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120
 45
 <210> 99
 <211> 120
 <212> PRT
 <213> Homo sapience
 50
 <400> 99
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 55 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Ser Asn

EP 3 037 819 A1

		20		25		30	
5	Ala Val Ser Trp Val Arg Gln	35	Ala Pro Gly Gln Gly Leu Glu Trp Met	40	45		
10	Gly Gly Ile Ile Ala Ile Phe Gly Thr Pro Lys Tyr Ala Gln Lys Phe	50	55	60			
15	Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr	65	70	75	80		
20	Met Glu Leu Ser Gly Leu Arg Tyr Glu Asp Thr Ala Val Tyr Tyr Cys	85	90	95			
25	Ala Arg Gly Pro Asn Tyr Tyr Glu Ser Tyr Phe Asp Tyr Trp Gly Gln	100	105	110			
30	Gly Thr Leu Val Thr Val Ser Ser	115	120				
35	<210> 100						
40	<211> 120						
45	<212> PRT						
50	<213> Homo sapience						
55	<400> 100						
60	Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser	1	5	10	15		
65	Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Lys Asn	20	25	30			
70	Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met	35	40	45			
75	Gly Gly Ile Ile Ala Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe	50	55	60			
80	Gln Gly Arg Val Thr Ile Thr Ala Asp Asp Ser Thr Asn Thr Val Tyr	65	70	75	80		
85	Met Glu Leu Thr Ser Leu Arg Tyr Glu Asp Thr Ala Val Tyr Tyr Cys	85	90	95			
90	Ala Arg Gly Pro Asn Tyr Tyr Glu Asn Tyr Phe Asp Phe Trp Gly Gln	100	105	110			
95	Gly Thr Leu Val Thr Val Ser Ser						

EP 3 037 819 A1

115

120

5

<210> 101
<211> 120
<212> PRT
<213> Homo sapience

<400> 101

10

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Lys Ser
20 25 30

20

Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Ile Ile Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60

25

Gln Asp Arg Val Thr Ile Thr Ala Asp Asp Ser Thr Asn Thr Val Tyr
65 70 75 80

30

Met Glu Leu Thr Ser Leu Arg Tyr Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Pro Asn Tyr Tyr Glu Ser Tyr Leu Asp Phe Trp Gly Gln
100 105 110

35

Gly Thr Thr Val Thr Val Ser Ser
115 120

40

<210> 102
<211> 120
<212> PRT
<213> Homo sapience

<400> 102

45

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

50

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Ser His
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

55

Gly Gly Ile Ile Ala Ile Phe Gly Thr Thr His Tyr Ala Gln Gln Phe
50 55 60

EP 3 037 819 A1

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Tyr
 65 70 75 80

 5 Met Glu Leu Ser Thr Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

 10 Ala Arg Gly Pro Asn Tyr Phe Glu Ser Tyr Phe Asp Asn Trp Gly Gln
 100 105 110

 Gly Thr Leu Val Thr Val Ser Ser
 115 120

 15
 <210> 103
 <211> 120
 <212> PRT
 <213> Homo sapience

 20
 <400> 103

 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

 25 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Ile Phe Asn Lys Phe
 20 25 30

 30 Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

 Gly Gly Ile Thr Ala Leu Phe Ala Thr Thr Ser Tyr Ala Gln Lys Phe
 50 55 60

 35
 Gln Asp Arg Val Thr Ile Asn Trp Asp Glu Ser Thr Thr Thr Ala Phe
 65 70 75 80

 40 Met Glu Leu Ser Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

 45 Ala Arg Gly Pro Asn Tyr Tyr Glu Thr Tyr Leu Asp Asn Trp Gly Gln
 100 105 110

 Gly Thr Leu Val Thr Val Ser Ser
 115 120

 50
 <210> 104
 <211> 122
 <212> PRT
 <213> Homo sapience

 55
 <400> 104

EP 3 037 819 A1

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 5 Ser Val Lys Val Ser Cys Ser Phe Lys Ala Ser Gly Gly Ile Ile Ser
 20 25 30
 10 Lys Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
 35 40 45
 Trp Met Gly Gly Ile Ile Ala Ile Phe Gly Ser Thr Asn Tyr Ala Gln
 50 55 60
 15 Lys Phe Gln Gly Arg Leu Thr Ile Thr Ser Asp Glu Ser Thr Ser Thr
 65 70 75 80
 20 Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
 85 90 95
 Tyr Cys Gly Arg Gly Pro His Tyr Tyr Glu Ser His Leu Asp Tyr Trp
 100 105 110
 25 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120
 30 <210> 105
 <211> 120
 <212> PRT
 <213> Homo sapience
 35 <400> 105
 Gln Val Gln Leu Val Gln Ser Gly Ser Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 40 Ser Val Lys Val Ser Cys Lys Ser Ser Gly Gly Ile Leu Arg Arg Ser
 20 25 30
 45 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Gly Ile Leu Ala Ile Phe Gly Thr Thr Lys Tyr Ala Gln Lys Phe
 50 55 60
 50 Gln Gly Arg Ile Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Val His
 65 70 75 80
 55 Met Glu Leu Ser Ser Leu Arg Pro Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

EP 3 037 819 A1

Ala Gly Gly Pro His Tyr Tyr Val Ser Tyr Phe Asp Ser Trp Gly Gln
100 105 110

5 Gly Thr Leu Val Thr Val Ser Ser
115 120

10 <210> 106
<211> 120
<212> PRT
<213> Homo sapience

<400> 106

15 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

20 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Asn Lys Tyr
20 25 30

Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25 Gly Gly Ile Leu Ala Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe
50 55 60

30 Gln Gly Arg Val Thr Ile Ser Ala Asp Glu Ser Ser Thr Thr Val Tyr
65 70 75 80

35 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Asn Thr Tyr Tyr Ser Ser Tyr Phe Asp Gln Trp Gly Gln
100 105 110

40 Gly Thr Leu Val Thr Val Ser Ser
115 120

45 <210> 107
<211> 120
<212> PRT
<213> Homo sapience

50 <400> 107

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Val Lys Lys Pro Gly Ser
1 5 10 15

55 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Asn Ser Tyr
20 25 30

EP 3 037 819 A1

	Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
5	Gly	Gly	Ile	Leu	Ala	Ile	Phe	Gly	Thr	Thr	Asn	Tyr	Ala	Gln	Lys	Phe	
		50					55					60					
	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Asp	Ser	Ser	Lys	Thr	Val	Tyr	
10	65					70					75					80	
	Met	Glu	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
15	Ala	Arg	Gly	Ser	Thr	Tyr	Tyr	Ser	Ser	Tyr	Phe	Asp	Gln	Trp	Gly	Gln	
				100					105					110			
	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser									
20			115					120									
	<210>		108														
	<211>		120														
25	<212>		PRT														
	<213>		Homo sapience														
	<400>		108														
	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ser	Glu	Val	Lys	Lys	Pro	Gly	Ser	
30	1				5					10					15		
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Ile	Phe	Arg	Thr	Asn	
35				20					25					30			
	Ala	Ile	Ser	Tyr	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35					40					45				
40	Gly	Gly	Ile	Thr	Ala	Ile	Phe	Gly	Thr	Pro	Asn	Tyr	Ala	Gln	Lys	Phe	
		50					55					60					
	Gln	Gly	Arg	Val	Thr	Ile	Ile	Ala	Asp	Glu	Ser	Thr	Ser	Thr	Val	Tyr	
45	65					70					75					80	
	Met	Glu	Leu	Gly	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
50	Ala	Thr	Ser	Gly	Thr	Tyr	Tyr	Val	Ser	Tyr	Phe	Asp	Ser	Trp	Gly	Gln	
				100					105					110			
	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser									
55			115					120									

EP 3 037 819 A1

<210> 109
 <211> 120
 <212> PRT
 <213> Homo sapience

5

<400> 109

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

10

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Lys Asn
 20 25 30

15

Ala Ile Ser Tyr Val Arg Gln Ala Pro Gly Gln Gly Val Glu Trp Met
 35 40 45

Gly Gly Ile Thr Ala Ile Phe Gly Thr Pro Asn Tyr Ala Gln Lys Phe
 50 55 60

20

Gln Gly Arg Ile Thr Ile Ser Ala Asp Glu Ser Thr Asn Thr Val Tyr
 65 70 75 80

25

Met Glu Leu Gly Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

30

Ala Thr Ser Gly Thr Tyr Tyr Val Ser Tyr Leu Asp Ser Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser
 115 120

35

<210> 110
 <211> 120
 <212> PRT
 <213> Homo sapience

40

<400> 110

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

45

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Gly Thr Leu Arg Ser Tyr
 20 25 30

50

Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Met
 35 40 45

Gly Gly Ile Ser Ala Ile Phe Asn Thr Ala Thr Tyr Ala Gln Asn Val
 50 55 60

55

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Thr Phe Tyr

EP 3 037 819 A1

	65		70		75		80									
5	Leu	Glu	Val	Ser	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95		
10	Ala	Thr	Ser	Gly	Thr	Tyr	Tyr	Val	Ser	Phe	Phe	Asp	Tyr	Trp	Gly	Gln
			100						105					110		
15	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser								
			115					120								
20	<210>	111														
	<211>	120														
	<212>	PRT														
	<213>	Homo sapience														
25	<400>	111														
	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	
30	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	His	Phe	Asn	Ala	Tyr
			20						25					30		
35	Gly	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
			35					40					45			
40	Gly	Gly	Ile	Val	Ala	Leu	Phe	Gly	Thr	Thr	Asn	Tyr	Ala	Gln	Lys	Leu
		50					55					60				
45	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Ala	Ser	Thr	Asn	Thr	Val	Tyr
	65					70					75					80
50	Met	Glu	Leu	Thr	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85						90					95	
55	Ala	Arg	Ser	Gly	Ser	Tyr	Tyr	Pro	Asp	Tyr	Phe	Gln	Tyr	Trp	Gly	Gln
			100						105					110		
60	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser								
			115					120								
65	<210>	112														
	<211>	120														
	<212>	PRT														
	<213>	Homo sapience														
70	<400>	112														
	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ser	Glu	Val	Lys	Lys	Pro	Gly	Ser
	1				5					10					15	

EP 3 037 819 A1

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Val Thr Phe Ser Ser Tyr
20 25 30

5 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

10 Gly Gly Ile Ser Pro Met Phe Gly Thr Thr Arg Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Arg Thr Gly Phe
65 70 75 80

15 Met Glu Leu Ser Ser Leu Arg Ser Gly Asp Thr Ala Val Tyr Tyr Cys
85 90 95

20 Ala Arg Ser Pro Thr Tyr Tyr Pro Gly Ala Leu Asp Met Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

25

<210> 113
<211> 120
<212> PRT
30 <213> Homo sapience

<400> 113

Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

35 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ser Ile Phe Ser Asn Tyr
20 25 30

40 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

45 Gly Gly Ile Val Pro Met Phe Gly Thr Thr Arg Phe Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Arg Ser Thr Ala Tyr
65 70 75 80

50 Met Glu Leu Asn Asn Leu Ile Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

55 Ala Arg Ala Pro Leu Ile Tyr Asn Trp Tyr Phe Asp Leu Trp Gly Arg
100 105 110

EP 3 037 819 A1

Gly Thr Leu Val Thr Val Ser Ser
115 120

5
<210> 114
<211> 120
<212> PRT
<213> Homo sapience

10
<400> 114

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15
Ser Val Lys Val Ser Cys Gln Ala Ser Gly Ser Ile Phe Ser Asn Tyr
20 25 30

20
Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

25
Gly Gly Ile Val Pro Ile Phe Gly Thr Thr Arg Phe Ala Gln Lys Phe
50 55 60

Gln Gly Arg Leu Thr Ile Thr Ala Asp Glu Pro Arg Ser Thr Ala Tyr
65 70 75 80

30
Met Glu Leu Asn Asn Leu Ile Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

35
Ala Arg Ala Pro Leu Ile Tyr Asn Trp Tyr Tyr Asp Leu Trp Gly Arg
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

40
<210> 115
<211> 121
<212> PRT
45
<213> Homo sapience

<400> 115

Gln Val Gln Leu Gln Gln Ser Gly Ala Asp Val Lys Lys Ala Gly Ser
1 5 10 15

50
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Arg Thr Phe Gly Asn Tyr
20 25 30

55
Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

EP 3 037 819 A1

	Gly	Gly	Ile	Thr	Pro	Ile	Phe	Gly	Ala	Ala	Asn	Tyr	Ala	Gln	Lys	Phe	
	50						55					60					
5	Gln	Gly	Arg	Val	Thr	Ile	Ser	Ala	Asp	Leu	Ser	Thr	Arg	Met	Val	Tyr	
	65					70					75					80	
	Met	Asp	Leu	Ser	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Phe	Tyr	Tyr	Cys	
10					85					90					95		
	Ala	Gly	His	Pro	Thr	Tyr	His	Tyr	Gly	Ser	Ala	Met	Asp	Tyr	Trp	Gly	
				100					105					110			
15	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser								
			115					120									
20	<210>	116															
	<211>	121															
	<212>	PRT															
	<213>	Homo sapience															
	<400>	116															
25	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Asp	Val	Lys	Lys	Pro	Gly	Ser	
	1				5					10					15		
	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Thr	Phe	Gly	Asn	Tyr	
30				20					25					30			
	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	
			35				40						45				
35	Gly	Gly	Ile	Thr	Pro	Ile	Phe	Gly	Pro	Ala	Asn	Tyr	Ala	Gln	Arg	Phe	
	50						55					60					
40	Gln	Gly	Arg	Val	Thr	Ile	Ser	Ala	Asp	Ile	Ser	Thr	Arg	Thr	Ala	Tyr	
	65					70				75					80		
	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Ile	Tyr	Tyr	Cys	
45				85					90					95			
	Ala	Arg	His	Pro	Thr	Tyr	Tyr	Phe	Gly	Ser	Ala	Met	Glu	Tyr	Trp	Gly	
				100					105					110			
50	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser								
			115					120									
55	<210>	117															
	<211>	121															
	<212>	PRT															

EP 3 037 819 A1

<213> Homo sapience

<400> 117

5 Gln Val Gln Leu Val Gln Ser Gly Ala Asp Val Lys Lys Pro Gly Ser
1 5 10 15

10 Ser Val Arg Val Ser Cys Lys Ala Ser Gly Arg Thr Phe Gly Asn Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

15 Gly Gly Ile Thr Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
50 55 60

20 Gln Gly Arg Val Thr Ile Ser Ala Asp Leu Ser Thr Thr Met Val Tyr
65 70 75 80

25 Met Asp Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Phe Tyr Tyr Cys
85 90 95

Ala Gly His Pro Thr Tyr Tyr Tyr Gly Ser Pro Met Asp Tyr Trp Gly
100 105 110

30 Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 118

<211> 121

<212> PRT

<213> Homo sapience

<400> 118

40 Gln Val Gln Leu Val Gln Ser Gly Ala Asp Val Lys Lys Ala Gly Ser
1 5 10 15

45 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Arg Thr Phe Gly Asn Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

50 Gly Gly Ile Thr Pro Ile Phe Gly Ala Ala Asn Tyr Ala Gln Lys Phe
50 55 60

55 Gln Gly Arg Val Thr Ile Ser Ala Asp Leu Ser Thr Arg Met Val Tyr
65 70 75 80

EP 3 037 819 A1

Met Asp Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Phe Tyr Tyr Cys
85 90 95

5 Ala Gly His Pro Met Tyr His Tyr Gly Ser Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

10

<210> 119
<211> 121
<212> PRT
<213> Homo sapience

15

<400> 119

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

20

Ser Val Lys Val Ser Cys Glu Ala Ser Gly Ala Thr Phe Ser Ser Asn
20 25 30

25

Ala Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met
35 40 45

30

Gly Gly Ile Ile Thr Met Phe Arg Lys Ala Glu Tyr Ala Gln Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Gly Glu Leu Gly Ser Thr Ala Tyr
65 70 75 80

35

Met Glu Val Arg Ser Leu Thr Phe Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

40

Ala Arg His Ser Gly Tyr His Leu Ile Gly Tyr Phe Asp Ser Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

45

<210> 120
<211> 122
<212> PRT
<213> Homo sapience

50

<400> 120

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Arg Lys Pro Gly Ser
1 5 10 15

55

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Val Ile Phe Ile Lys Phe

EP 3 037 819 A1

		20		25		30										
5	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35						40					45			
10	Gly	Gly	Ile	Ile	Pro	Met	Phe	Gly	Thr	Thr	Asn	Tyr	Ala	Gln	Lys	Phe
		50					55					60				
15	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Gly	Ser	Thr	Asn	Thr	Val	Tyr
	65					70					75				80	
20	Met	Glu	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85						90					95	
25	Ala	Lys	Glu	Glu	Gly	Tyr	Tyr	Tyr	Gly	Ser	Gly	Pro	Leu	Asp	Ser	Trp
				100					105					110		
30	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser						
			115					120								
35	<210>	121														
	<211>	122														
	<212>	PRT														
	<213>	Homo sapience														
40	<400>	121														
45	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Val	Lys	Gln	Pro	Gly	Ser
	1			5						10				15		
50	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Ile	Phe	Arg	Ser	Asn
			20						25					30		
55	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met
		35						40					45			
60	Gly	Gly	Ile	Val	Ala	Leu	Phe	Gly	Thr	Ala	Asn	Tyr	Ala	Gln	Lys	Phe
		50					55					60				
65	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Glu	Ser	Thr	Ser	Thr	Val	Tyr
	65					70					75				80	
70	Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Arg	Tyr	Tyr	Cys
				85						90				95		
75	Ala	Arg	Asn	Ser	Gly	Tyr	His	Ile	Ser	Gly	Phe	Tyr	Leu	Asp	Tyr	Trp
			100						105					110		
80	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser						

EP 3 037 819 A1

115

120

5

<210> 122
<211> 122
<212> PRT
<213> Homo sapience

<400> 122

10

Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Pro Phe Arg Ser His
20 25 30

20

Ala Ile Ser Trp Val Arg Gln Ala Ala Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Gly Ile Thr Ala Val Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

25

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Asn Ile Val Ser
65 70 75 80

30

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Ser Leu Gly Tyr His Thr Gln Tyr Asn Gly Met Asp Val Trp
100 105 110

35

Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

40

<210> 123
<211> 124
<212> PRT
<213> Homo sapience

<400> 123

45

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

50

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Arg Lys Asn
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

55

Gly Gly Ile Ser Ala Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

EP 3 037 819 A1

	Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Glu	Ser	Ser	Asn	Thr	Val	Tyr	65	70	75	80
5	Met	Asp	Leu	Ser	Arg	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Ile	Tyr	Tyr	Cys	85	90	95	
10	Ala	Ser	His	Pro	Thr	Tyr	His	Phe	Asp	Lys	Ser	Gly	Tyr	Arg	Phe	Asp	100	105	110	
15	Ser	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser					115	120		
20	<210>	124																		
	<211>	124																		
	<212>	PRT																		
	<213>	Homo sapience																		
25	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ser	1	5	10	15
30	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Gly	Ile	Phe	Asn	Ser	Asn	20	25	30	
35	Ala	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met	35	40	45	
40	Gly	Gly	Ile	Ile	Gly	Ile	Phe	Gly	Thr	Ala	Asn	Tyr	Ala	Gln	Lys	Phe	50	55	60	
45	Gln	Gly	Arg	Val	Thr	Ile	Ala	Ala	Asp	Gln	Ser	Thr	Asn	Thr	Val	Phe	65	70	75	80
50	Met	Glu	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Phe	Cys	85	90	95	
55	Ala	Arg	Ser	Arg	Gly	Tyr	Ser	Phe	Gly	Tyr	Gly	Thr	Asp	Tyr	Phe	Asp	100	105	110	
	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser					115	120		
	<210>	125																		
	<211>	124																		
	<212>	PRT																		
	<213>	Homo sapience																		
	<400>	125																		

EP 3 037 819 A1

Gln Val Gln Leu Val Gln Ser Gly Ser Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 5 Ser Val Lys Val Ser Cys Lys Ala Ser Arg Gly Ile Phe Ser Ser Tyr
 20 25 30
 10 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ala Val Ile Pro Met Phe Gly Thr Leu Lys Tyr Ala Glu Asn Phe
 50 55 60
 15 Gln Gly Arg Ile Thr Ile Ser Ala Asp Lys Ser Met Ser Ala Ala Tyr
 65 70 75 80
 20 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 25 Ala Arg Asn Tyr Tyr Gly Ser Gly Thr Tyr Phe Asn Asp Ala Phe Asp
 100 105 110
 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 115 120
 30 <210> 126
 <211> 126
 <212> PRT
 <213> Homo sapience
 35 <400> 126
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15
 40 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Phe
 20 25 30
 45 Ser Thr Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 35 40 45
 Glu Trp Met Gly Arg Ser Ile Pro Leu Leu Gly Ile Thr Asn Tyr Ala
 50 55 60
 50 Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Ile Ser Thr Ser
 65 70 75 80
 55 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
 85 90 95

EP 3 037 819 A1

Tyr Tyr Cys Ala Arg Tyr Gln Ser Ser Asp Tyr Tyr Asn Ser Glu Tyr
100 105 110

5 Phe Gln His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

10 <210> 127
<211> 296
<212> DNA
<213> Homo sapience

<400> 127
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggctc 60
15 tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac 180
20 gcacagaagt tccagggcag agtcacgatt accgcgagc aatccacgag cacagcctac 240
atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaga 296

25 <210> 128
<211> 98
<212> PRT
<213> Homo sapience

<400> 128
30 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

35 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

40 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

45 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

50 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg

55 <210> 129
<211> 20

<212> DNA
 <213> Artificial Sequence

<220>
 <223> primer T7ETZ

<400> 129
 taatacgact cactataggg

20

Claims

1. A method of determining resistance to a type A influenza virus by using the presence or absence of an antibody using VH1-69 gene in a biological sample derived from a subject.
2. The method according to claim 1, comprising the following steps (1) to (3):
 - (1) a step of bringing a biological sample of a subject that has received an influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene;
 - (2) a step of detecting a generated immune complex;
 - (3) a step of determining the intensity of the resistance to a type A influenza virus based on the detection result in the step (2), wherein the amount of the detected immune complex serves as an indicator of the intensity of the resistance to the type A influenza virus.
3. The method according to claim 2, further comprising the following step:
 - (4) a step of detecting an immune complex generated by bringing a biological sample of a subject before receiving the influenza vaccine into contact with an anti-idiotypic antibody that recognizes an antibody using VH1-69 gene, comparing the amount of the immune complex with the amount of the immune complex detected in the step (2), and determining the intensity of the resistance based on the result of the comparison.
4. The method according to claim 2 or 3, wherein the biological sample is a blood sample.
5. The method according to any one of claims 1 to 4, wherein the type A influenza virus is one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H3N2, H5N1, H5N2, H6N1, H7N2, H7N3, H7N7, H7N9, H9N2 and H9N1.
6. The method according to any one of claims 1 to 4, wherein the type A influenza virus is one or more viruses selected from the group consisting of H1N1,
7. The method according to any one of claims 1 to 4, wherein the type A influenza virus is one or more viruses selected from the group consisting of H1N1, H1N2, H2N2, H5N1 and H5N2.
8. A kit for detecting resistance to a type A influenza virus, comprising an anti-idiotypic antibody that specifically recognizes an antibody using VH1-69 gene.

Gr. clone	Unique clone	Number of isolated clone from each library		Representative clone	Germline identity	Amino acid sequences for CDR3 region of clone	HI titer (mg/ml)	Binding activity					Focus reduction activity (%)									
		Cal09 Before	Br07 After					Br07	NC99	S106	Br07	H1N1	Br07	H1N1		H5N1						
														250	100	250	100	250	100			
5	1	2	2	F082-124	1-18*01	94.3 DTTVTNNEEINFFYGMVDV	-	20	0.09	0.09	0.16	0.13	0.22									
4	5	42	42	F082-001	1-18*01	97.7 DTEVTNNEEINFFYGMVDV	-	20	0.09	0.08	0.15	0.13	0.23	23.8	-8.2	100	100					
7	1	1	1	F082-289	1-18*01	97.7 DTEVTSEEINFFYGMVDV	-	10	0.11	0.09	0.20	0.29	0.15	0.28								
6	2	2	2	F082-355	1-18*01	98.9 DTTVTSEEINFFYGMVDV	-	20	0.09	0.09	0.14	0.28	0.13	0.22								
8	6	6	6	F082-109	1-46*01	96.6 EFGANGEDIYFHGMVDV	-	10	0.15	0.08	0.14	0.23	0.20	26.2	6.6	86.5	54.5					
9	1	1	1	F082-022	2-5*09	98.9 SIGGYDGEIGFNNHYGMVDV	-	160	0.09	0.08	0.14	0.28	0.12	0.19	45.9	26.2	17.4	15.7				
10	1	1	1	F082-380	3-7*01	96.6 DEWFGEIGSSGMVDV	-	20	0.14	0.11	0.30	0.15	0.40	0.47	18.9	11.5	100	94.9				
11	1	1	1	F082-290	3-9*01	95.5 DFAGEGHGSSGVVDY	-	20	0.10	0.10	0.20	0.30	0.20	0.26	58.2	41.0	74.7	46.1				
12	1	1	1	F082-122	3-21*01	86.4 SATSYRDYLDROFFYYALDV	-	10	0.21	0.13	0.38	0.13	0.16	0.26	60.7	68.0	69.7	49.4				
13	1	1	1	F082-262	3-21*01	86.4 SATSYRDYLDROFFYYALDV	-	10	0.10	0.08	0.15	0.30	0.15	0.22								
14	1	2	2	F082-105	3-30*01	96.6 DHLNSELVATITGFGLDY	-	5	0.10	0.09	0.18	0.32	0.14	0.26	13.9	6.6	100	100				
15	1	1	1	F082-393	3-30*01	93.2 DKLNSEMVATITGFGLDY	-	10	0.08	0.08	0.15	0.30	0.12	0.22								
16	1	1	1	F082-392	3-30*01	94.3 DKLNSEMVATITGFGLDY	-	10	0.09	0.08	0.13	0.18	0.12	0.16								
20	1	1	1	F082-108	3-30*03	95.5 DKLNSDEVTTITGFGLDY	-	2.5	0.13	0.13	0.24	0.30	0.15	0.32								
17	1	1	1	F082-102	3-30*01	90.9 DNLNSELVATITGFGLDH	-	5	0.09	0.10	0.18	0.37	0.15	0.25								
18	1	1	1	F082-376	3-30*01	97.7 DNLNSELVATITGFGLDY	-	20	0.09	0.09	0.15	0.15	0.13	0.21								
19	1	1	1	F082-005	3-30*01	95.5 DYLNSEMVATITGFGLDS	-	40	0.10	0.09	0.14	0.27	0.12	0.15								
21	2	7	7	F082-104	3-30*01	94.3 EPSNTEDIRGIEGVFDY	-	2.5	0.14	0.13	0.23	0.30	0.20	0.33	-0.8	18.9	93.3	84.8				
22	1	1	1	F082-254	3-30*02	81.8 DAYSSGDYTYGLDV	-	10	0.91	0.55	0.48	0.84	0.12	0.16	100	100	100	100				
23	2	2	2	F082-003	3-43*02	95.5 DRGTGEQIAVVTALIDY	-	2.5	0.08	0.08	0.15	0.18	0.14	0.22	77.9	38.5	100	98.3				
24	1	2	2	F082-332	4-39*01	95.5 HGYDXYGYFDY	-	20	0.11	0.10	0.24	0.30	0.16	0.35	33.6	1.6	100	100				
25	4	6	6	F082-208	4-59*01	96.6 VLRWLGEEDADAFDI	-	10	0.10	0.08	0.16	0.30	0.14	0.24	1.6	11.5	32.6	25.8				
26	1	1	1	F082-341	4-59*01	82.8 GFGMVGDVTVDLYNGMDV	-	10	0.11	0.09	0.20	0.29	0.16	0.31	21.3	16.4	100	100				
27	1	2	2	F082-351	4-59*01	97.7 VQRPYGDYAAAGAFDI	-	10	0.10	0.10	0.20	0.30	0.16	0.27	36.1	-15.6	100	96.6				
28	1	1	1	F082-120	4-59*01	94.3 VQRPYGDYITGAFDI	-	10	0.11	0.11	0.14	0.69	0.12	0.18								
29	1	1	1	F082-352	5-51*01	97.7 RTWYDGSQDPSRDADFI	-	10	0.10	0.10	0.20	0.30	0.14	0.25	18.9	6.6	100	100				
30	1	1	1	F082-316	7-4-1*02	100 DLNGEDIAVQPGTIGVDY	-	5	0.10	0.08	0.16	0.30	0.14	0.23								
31	1	2	2	F082-020	7-4-1*02	100 DLNGEDIAVQPGTIGVDY	-	5	0.10	0.10	0.19	0.30	0.59	0.30	48.4	32.0	98.3	98.3	6.6	10.5	-2.7	2.7
32	1	1	1	F082-359	7-4-1*02	97.7 DLNGEDIAVQPGTIGVDY	-	5	0.18	0.18	0.22	0.30	0.25	0.24								
33	3	3	3	F082-317	7-4-1*02	96.6 GTEVTTEEIYFYGMVDV	-	20	0.16	0.17	0.28	0.30	0.19	0.35	-0.8	16.4	71.3	36.0				
34	1	1	1	F082-248	7-4-1*02	96.6 GTEVTTEEIYFYGMVDV	-	20	0.09	0.08	0.17	0.30	0.14	0.17								
46	1	1	1	F083-116	1-3*01	87.5 AEKWLADYFYFYGMVDV	>160	20	0.36	0.17	0.17	0.36	0.17	0.17	93.0	81.3	54.5	42.7	34.2	21.1	5.6	-11.9

Number of isolated clone from each library				Unique Isolated clone	Number	Amino acid sequences for CDR3 region of clone			H1 titer (mg/ml)	Binding activity			Focus reduction activity (%)							
Gr.	Cal09 Before	Br07 After	Representative clone			Germine Identity (%)	Germine Identity (%)	H1N1		H3N2	H1N1		H5N1		H3N2					
											Br07	Sui09	Br07	Sui09	Br07	Sui09	Br07	Sui09		
66	1		1	F083-341	1-46*01	89.8	DREESLFAGAIYNYIDMDV	>160	80	2.572.562.431.24	0.290.26	95.3	85.9	100	94.9	98.7	90.8	2.1	-18.4	
45	1		1	F081-268	4-34*01	97.7	KGAKLLYFDWLASAFDI	>80	>160	2.492.271.891.13	0.230.21	nd	41.4	nd	57.9	nd	63.2	nd	-19.7	
1	2	1	4	F080-227	1-69*01	92.2	GPVYENEFY	>160	>160	3.153.163.102.92	0.140.15	98.0	98.0	100	100	52.9	67.6	-0.7	-0.7	
2	4	1	1	F082-220	1-69*01	88.6	GPVYESYFY	>160	>160	3.373.373.152.72	0.160.24	100	100	97.7	95.3	97.1	90.6	34.2	3.4	
36	2		1	F082-243	1-69*01	88.6	GPVYENYDF	>160	>160	0.961.211.05.80	0.130.11	94.1	84.2	85.9	97.7	52.9	50.6	-2.7	7.5	
49	1		1	F083-115	1-69*01	85.2	GPVYESYDF	>160	>160	2.562.492.231.83	0.270.28	100	96.1	83.6	93.0	89.4	91.8	91.8	54.8	
47	2		7	F083-308	1-69*01	89.8	GPVYESYDFN	>160	>160	1.791.921.821.2	0.160.14	100	100	100	97.7	49.4	29.4	-6.8	1.4	
48	2		2	F083-389	1-69*01	79.5	GPVYETYDFN	>160	>160	2.722.802.832.45	0.140.15	100	98.0	100	100	18.3	60.8	54.6	19.9	-0.7
3	2	1	1	F081-281	1-69*01	85.6	GPVYESHLY	>160	>160	2.862.862.982.87	0.180.24	100	98.0	100	100	85.9	81.8	-8.9	11.6	
35	1		1	F082-117	1-69*01	80.7	GPVYVSYFDS	>160	>160	3.353.373.263.1	0.150.12	100	100	100	100	95.9	94.1	-4.8	3.4	
39	2	2	2	F082-237	1-69*01	86.4	GNTYSSYFDQ	>160	>160	1.941.691.952.52	0.130.14	64.5	48.7	100	95.3	41.2	31.2	15.8	-2.7	
54	1	3	3	F083-354	1-69*01	87.5	GSTYSSYFDQ	>160	>160	3.052.923.012.54	0.160.18	100	96.1	94.2	100	80.7	66.4	-11.0	-0.7	
37	2		1	F083-311	1-69*01	85.2	SGTYVVSFYDS	>160	>160	2.592.702.641.8	0.150.17	100	100	100	93.0	97.1	90.0	5.5	-8.9	
41	2		3	F081-107	1-69*01	81.8	SGTYVVSFYDS	>160	>160	2.923.022.942.66	0.150.19	92.1	96.1	100	100	85.9	81.2	40.4	3.4	
52	1		1	F083-328	1-69*01	80.7	SGTYVVSFFDY	>160	>160	2.662.562.432.0	0.220.23	100	100	100	100	93.2	86.9	5.5	9.6	
40	3		2	F081-264	1-69*01	84.1	SGSYPDYFQY	>160	>160	3.103.263.073.03	0.190.40	100	98.0	100	100	97.6	94.1	-6.8	-8.9	
42	2		1	F083-249	1-69*01	89.8	SPTYPGALDM	>160	>160	3.133.163.022.83	0.150.20	100	100	97.7	100	98.2	96.5	34.2	15.8	
55	1		1	F083-305	1-69*01	86.4	APLYNWFYDL	>160	>160	3.073.072.881.22	0.150.19	96.1	96.1	69.5	88.3	22.4	2.4	-6.8	-17.1	
56	1		1	F083-318	1-69*01	83.0	APLYNWFYDL	>160	>160	3.012.902.850.71	0.160.27	92.1	8	27.9	13.5	1.7	-9.5	7.5	7.5	
57	1	2	2	F083-103	1-69*01	83.0	HPTVHYGSAMDY	>160	>160	2.432.612.391.82	0.160.19	92.1	84.2	83.6	60.2	61.2	30.0	13.7	11.6	
58	1	2	2	F083-307	1-69*01	89.8	HPTVYFGSAMEY	>160	>160	3.303.323.042.32	0.190.28	100	100	64.8	76.6	31.8	28.8	11.6	-6.8	
60	1		1	F083-373	1-69*01	83.0	HPTVYGSAMDY	>160	>160	1.392.401.131.3	0.170.130.18	74.3	70.4	7.7	1.9	15.4	-3.3	-21.2	-8.9	
59	1	1	1	F083-351	1-69*01	83.0	HPMYHYGSAMDY	>160	>160	3.232.63.092.62	0.210.30	100	100	85.6	88.5	5.4	-2.7	-6.8	-6.8	
61	1	2	2	F083-302	1-69*01	80.7	HSGVHLIGFYDS	>160	>160	1.922.682.901.55	0.230.11	98.0	98.0	100	100	85.9	72.9	-11.0	3.4	
62	2		2	F083-349	1-69*01	85.2	EEGYVYSGFLDS	>160	>160	3.173.082.932.71	0.150.15	92.1	92.1	91.3	97.1	63.9	40.2	-8.9	13.7	
63	1		1	F083-336	1-69*01	89.8	NSGVHISGFYDY	>160	>160	1.811.911.991.55	0.150.13	100	100	100	100	100	98.8	-8.9	-11.0	
38	2		1	F082-338	1-69*01	86.4	SLGHVTVQNGMDV	>160	>160	3.012.882.932.83	0.130.12	100	100	97.7	100	85.3	67.1	-0.7	-2.7	
43	1		2	F081-007	1-69*01	85.2	HPTVHFDSGYRFDY	>160	>160	2.842.822.723.3	0.140.13	100	100	100	100	98.8	97.6	13.7	11.6	
64	1		1	F083-301	1-69*01	87.5	SRGVSFGYTDYFY	>160	>160	1.341.511.441.1	0.460.160.13	92.1	86.2	81.3	83.6	47.1	40.6	7.5	-2.7	
65	1		1	F083-366	1-69*01	84.1	NYGSGTYFNDAFDI	>160	>160	2.932.612.641.1	0.180.26	98.0	96.1	19.2	13.5	-3.9	-0.8	-6.8	-13.0	
44	1		1	F081-008	1-69*02	92.3	YQSSDYINSEYFQH	>160	>160	3.283.172.551.3	0.430.190.22	100	100	97.7	95.3	56.5	48.8	15.8	3.4	

Fig. 1 (continued)

		Fab-pp																
	F082-001	F082-332	F082-341	F082-020	F082-351	F082-122	F082-104	F082-208	F082-109	F082-352	F082-003	F082-105	F082-290	F082-380	F082-317	F082-254	F082-022	
Fab-cp3	F082-001	107.0	87.7	96.0	100.1	99.6	96.5	96.7	96.1	97.2	96.0	98.7	99.0	81.3	96.5	80.0	96.7	53.5
	F082-332	89.1	89.8	92.9	94.2	84.6	93.4	88.4	81.8	92.6	93.5	93.2	93.5	95.5	91.9	96.7	92.6	69.4
	F082-341	90.7	90.1	99.0	97.7	95.6	94.7	94.3	102.1	96.2	97.6	99.7	100.3	92.6	96.1	99.9	95.6	72.7
	F082-020	100.1	100.0	100.2	100.3	102.5	98.2	97.1	108.9	99.8	97.7	99.4	99.7	92.8	96.5	100.1	60.6	64.3
	F082-351	91.5	103.1	101.2	104.8	99.9	96.1	100.7	107.8	101.6	99.2	102.5	102.2	95.9	100.4	100.7	94.9	68.1
	F082-122	72.4	84.9	87.5	86.5	71.4	93.5	71.2	71.1	86.1	89.7	87.7	84.2	87.9	82.7	94.1	94.3	63.5
	F082-104	100.7	92.2	97.8	97.6	99.2	89.9	96.7	98.7	72.6	97.7	97.9	97.2	95.2	96.6	98.6	85.6	72.5
	F082-208	87.7	94.3	94.7	96.1	91.9	95.6	95.8	96.0	96.9	96.6	96.9	97.1	93.6	94.9	97.1	91.3	69.8
	F082-109	92.4	98.4	94.3	97.1	93.2	94.3	94.2	103.3	96.5	96.6	97.0	97.3	86.9	96.1	99.3	92.7	74.4
	F082-352	93.0	101.8	98.4	99.5	88.6	92.3	96.0	92.7	97.2	96.5	98.3	98.9	94.1	94.5	97.3	91.7	67.5
	F082-003	98.2	81.1	96.5	89.6	90.3	90.6	79.9	89.6	88.4	92.4	85.6	86.6	71.8	89.3	97.4	95.0	32.5
	F082-105	93.6	99.0	99.1	96.0	101.1	95.8	95.3	102.6	98.1	97.9	98.0	97.7	89.7	97.2	99.3	97.8	60.3
	F082-290	90.1	96.0	76.3	79.2	97.9	97.2	100.2	98.7	100.6	78.1	99.3	101.7	95.4	97.4	87.2	86.0	88.8
	F082-380	91.8	85.4	95.1	92.0	79.6	78.1	86.6	79.8	91.9	88.0	89.7	90.6	79.4	85.3	94.1	79.8	67.2
	F082-317	76.6	87.2	74.9	82.1	71.3	45.3	69.6	84.0	80.9	82.2	77.7	84.0	82.8	83.9	90.4	87.6	40.7
	F082-254	79.6	81.0	72.7	50.1	63.8	67.8	39.3	28.7	44.4	48.9	57.3	62.8	67.2	57.2	63.7	84.6	34.3
	F082-022	79.2	86.7	72.0	62.6	64.7	81.7	52.5	57.9	79.8	82.0	71.6	79.7	77.2	73.7	91.2	89.2	31.8
	F008-009	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	F033-367	13.7	13.6	18.1	16.0	-14.9	5.4	-2.4	-17.7	9.7	1.6	5.5	4.4	-2.1	-2.3	-7.7	5.6	11.1

Fig. 2




Fig. 3




Fig. 4

Group	Clone	Primer	FR1	CDR1	FR2	CDR2	FR3	VH CDR3	VH FR4
5	F082-124	QVQLVQ SGSE	VKKPGASVKVS CKASGYTFT	SNGIS	WVRQAPG QGLEWMG	WISGLNGNT NYAQKLQG	RVTMTTDTSTSTAYME LRSLTSDDTAVYFCAR	DTTVTNEEIN FYYGMDV	WGQGT VTVSS
4	F082-001	QVQLVQ SGAE	MKKPGASVKVS CKASGYTFT	SYGIS	WVRQAPG QGLEWMG	WISANNNGT NYAQKLQG	RVTMTTDTSTSTAYME LRSLRSDDTAVYFCAR	DTEVTNEEIN FYYGMDV	WGQGT VTVSS
7	F082-289	EVQLVE SGAE	MKKPGASVKVS CKASGYTFT	SYGIS	WVRQAPG QGLEWMG	WISANNNGT NYAQKLQG	RVTMTTDTSTSTAYME LRSLRSDDTAVYFCAR	DTEVTSEEIN FYYGMDV	WGQGT VTVSS
6	F082-355	EVQLVE SGAE	VKKPGASVKVS CKASGYTFT	SYGIS	WVRQAPG QGLEWMG	WISAYNGNT NYAQKLQG	RVTMTTDTSTSTAYME LRSLRSDDTAVYFCAR	DTTVTSEEIN FYQGMDV	WGQGT VTVSS
8	F082-109	QVQLQE SGAE	VKKPGASVKVS CKASGYAFT	TYMH	WVRQAPG QGLEWMG	IINPSGGYT SYAQKFQG	RVTMTTRDTSTSTVYME LSSLRSEDATVYFCAR	EFGANGEDIY FYHGMDV	WGQGT VTVSS
9	F082-022	QVTLKE SGPT	LVKPTQTLLT CTFSGFSL	TSGVGVG	WIRQPPG KALEWLA	LIYWDKKR YSPSLKS	RLTITKDTSKNQVLT MTNMDPVDATYYCAH	SIGGYDGEI FYNHYGMDV	WGQGT VTVSS
10	F082-380	EVQLVE SGGN	LVQPGGSLRLS CAASGFTFS	SYWMT	WVRQAPG KGLEWVA	NIEQDGSEK FYVDVSKG	RFTISRDNKNSLYLQ MNSLRAEDTAVYFCAR	DEWFEGELGSS GMDV	WGQGT VTVSS
11	F082-290	QVQLQE SGGG	SVQPGSLRLS CAASGFTFD	DYAMH	WVRQAPG KGLEWVS	GISWHSGSI GYADSVKG	RFTISRDNKNSLYLQ MNSLRPEDTALYYCAK	DFAGEGHGSG SVDY	WGQGT VTVSS
12	F082-122	EVQLVE SGGG	PVKPGSLRLS CAASAFTR	TYDMN	WVRQAPG KGLEWVS	GISSSGDYI YYADSVQG	RFTISRDNKNSLYLQ LNSLRAEDTAVYFCAR	SATSYRDYLD RDFYYALDV	WGQGT VTVSS
13	F082-262	QVQLQE SGGG	LVKSGSLRLS CAASAFTR	TYDMN	WVRQAPG KGLEWVS	GISSSGDYI YYADSVQG	RFTISRDNKNSLYLQ LNSLRAEDTAVYFCAR	SATSYRDYLD RDFYYALDV	WGQGT VTVSS
14	F082-105	EVQLVE SGGG	VVQPGSLRLS CAASGFTFS	SYAMH	WVRQAPG KGLEWVA	VMSDGSGYK YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYFCAR	DHLNSEIVAT ITGFLDY	WGQGT VTVSS
15	F082-393	EVQLVE SGGG	VVQPGSLRLS CAASGFTFS	SYVMH	WVRQAPG KGLEWVA	VISDDGIYK YYADSVKG	RFTISRDNKNTLYLQ MNSLRGEDTTVYFCAR	DKLNSEMVAT ITGFLDY	WGQGT VTVSS
16	F082-392	EVQLVE SGGG	VVQPGSLRLS CAASGFTFS	SYAMH	WVRQAPG KGLEWVA	IISDDGTHK YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTALYYCAK	DKLNSEMVAT ITGFLDY	WGQGT VTVSS
20	F082-108	QVQLQE SGGG	VVQPGSLRLS CAASGFTFS	SYGMH	WVRQAPG KGLEWVA	VISNDGSNK YYADSVKG	RFTISRDNKNTMYLQ MNSLRAEDTAVYHCGR	DKLNSEVTT ITGFLDY	WGQGT VTVSS
17	F082-102	EVQLVE SGGG	VVQPGSLRLS CAVSGFTFS	SYAMH	WVRQAPG KGLEWVA	VVSDDES YK YYADSVKG	RFTISRDNKNTLYLQ INSLRAEDTAVYFCAR	DNLNSELVAT ITGFLDH	WGQGT VTVSS

Fig. 5

18	F082-376	QVQLQE SGG	VVQPGRLRLS CAASGFTFS	SYAMH	WVRQAPG KGLEWVA	VISNDGSNK YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYYCGR	DNLNSDEVAT ISGFLDY	WGQGTIL VTVSS
19	F082-005	QVQLVQ SGG	VVQPGRLRLS CAASGFTFS	GYAMH	WVRQAPG KGLEWVA	LISSDGSYK YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYYCAR	DYLNSEMVAT ITGFLDS	WGQGTIL VTVSS
21	F082-104	EVQLVE SGG	VVQPGRLRLS CAASGFSTFS	SYAVH	WVRQAPG KGLEWVA	DISYDGSNK YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYYCAT	EPSTEDIRG IEGVFDY	WGQGTIL VTVSS
22	F082-254	EVQLVE SGG	LVQPGGSLRLS CAASGFSTFS	QYGMH	WVRQAPG KGLEWVA	LIYYGGNPK SYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYYCAR	DAYSSGDTYY YGLDV	WGQGTIL VTVSS
23	F082-003	EVQLVE SGG	VVQPGGSLRLS CAASGFTFD	DYAMH	WVRRAPG KGLEWVS	VIDGDGGST YYADSVKG	RFTISRDNKNTLYLQ MNSLRAEDTAVYYCAR	DRGTGEQIAV VTALIDY	WGQGTIL VTVSS
24	F082-332	EVQLVE SGPG	LVKPSETLSLT CTVSGGSIS	SDSYWWD	WIRQPPG KGLEWIG	NIYSGSTY YNSSLKS	RVTISVDTSKNQFSLK LSSVTAADTAVYYCAR	HGYGDYVGYF DY	WGQGTIL VTVSS
25	F082-208	QVQLQE SGPG	LVKPSETLSLT CTVSGGSIS	SHYWS	WIRQTPG KGLEWIG	YIYGGSTN YNPSLKS	RVTISVDTSKNQFSLK LSSVTAADTAVYYCAR	VLRWLGEEDA DAFDI	WGQGTIL VTVSS
26	F082-341	EVQLVE SGPG	LVKPSETLSLT CTVSGGSMT	THYWN	WIRQPPG KALEWIG	NIYSGGTE YNPSLQS	RLTISLDTSKNQFSLT LTSVTAADTAVYYCAR	GFGMVGDITVD DLYNGMDV	WGQGTIL VTVSS
27	F082-351	EVQLVE SVPG	LVKPSETLSLT CTVSGGSIS	TYIWS	WIRQPPG KGLEWIG	YIYSGSTN YNPSLKS	RVTISVDTSKNQFSLK LRSVTAADTAVYYCAR	VQRPYGDYAA GAFDI	WGQGTIL VTVSS
28	F082-120	QVQLQE SGPG	LVKPSETLSLT CTVSGGSIS	TYIWS	WIRQPPG KGLEWVG	YIDYSGSTN YNPSLKS	RVTISVDTSKNQFSLI LRSVTAADTAVYYCAR	VQRPYGDYIT GAFDI	WGQGTIL VTVSS
29	F082-352	EVQLVE SGAE	VKKPGESLKIS CKSGYSFT	TYWIG	WVRQMPG KGLEWVG	IIPGDSDT RYSPSFQG	QVTISADKSIISTAYLQ WSSLKASDTGMYICAR	RTWYYDGSGP DPSRDAFDI	WGQGTIL VTVSS
30	F082-316	QVQLVQ SGSE	LKKPGASVKVS CKASGYTFT	SYAMN	WVRQAPG QGLEWVG	WINTNTGNP TYAQGFTG	REFVSLDTSVSTAYLQ ISSLKAEDTAVYYCAR	DLNGEDIAV QPGTIGVDY	WGQGTIL VTVSS
31	F082-020	QVQLVQ SGSE	LKKPGASVKVS CKASGYTFT	SYAMN	WVRQAPG QGLEWVG	WINTNTGNP TYAQGFTG	REFVSLDTSVSTAYLQ ISSLKAEDTAVYYCAR	DLNGEDIAV QPGTIGVDY	WGQGTIL VTVSS
32	F082-359	QVQLVQ SGSE	LKKPGASVKVS CKASGYTFS	SYAMN	WVRQAPG QGLEWVG	WINTNTGNP TYAQGFTG	REFVSLDTSVSTAYLQ ISSLKAEDTAVYYCAR	DLNGEDIAV QPATIGVDY	WGQGTIL VTVSS
33	F082-317	QVQLQQ SGSE	LKKPGASVKVS CKASGYTFS	SYGMN	WVRQAPG QGLEWVG	WINTNTGNP TYAQGFTG	REFVSLDTSVSTAYLQ ISSLKAEDTAVYYCAS	GTEVTTEEIY FYYGMDV	WGQGTIL VTVSS
34	F082-248	QVQLVQ SGSE	LKKPGASVKVS CKASGYTFTI	SYTMN	WVRQAPG QGLEWVG	WINTNTGNP RYAQGFTG	REFVSLDTSVSTAYLQ ISSLKAEDTAVYYCAR	GTEVTTEEIN FYYGMDV	WGQGTIL VTVSS

Fig. 5 (continued)

46	F083-116	QVQLVQ SGAE	VKPGASVKVS CKASGYIFN	SYAIIH	WVRQAPG QRPEWMG	WINIGNGNT KYSQKFQG	RVAITRDRSASTAYME VTSIRFEDTAVYYCAT	AEKWLADYFY YFGMDV	WGRGTT VTVSS
66	F083-341	EVQLVE SGAE	VKPGASVKVS CKASGYTFS	AYYIHH	WVRQSPG QGLEWMG	VINPSGGDT NYAQRFGQ	RLTMRDSTSTVYME LSSLRSEDSTAVYYCAR	DREESLFAGA IYNYYYDMDV	WQGTTT VTVSS
45	F081-268	QVQLQQ WGAG	LIKPESTLSLT CAVYGGSF	GYIWS	WIRQPPG KGLEWIG	EINHSGSTK NNPSLKS	RVTISVDTSKNQFSLK LSSVTAADTAVYYCAR	KGAKLLYFD WLASAFDI	WQGTTT VTVSS
1	F080-227	QVQLQE SGAE	VKPGSSVKVS CKASGGIFR	RNAIS	WVRQAPG QGLEWMG	GIIAIFGTA NYAQKFQG	RVTITADESTSTVYME LSSLRPEDTAVYYCAR	GPNNYENFFD Y	WQGTL VTVSS
2	F082-220	QVQLVQ SGAE	VKPGSSVKVS CKASGGIFR	SNAVS	WVRQAPG QGLEWMG	GIIAIFGTP KYAQKFQG	RVTITADESTSTVYME LSGLRYEDTAVYYCAR	GPNNYESYFD Y	WQGTL VTVSS
36	F082-243	QVQLQQ SGAE	VKPGSSVKVS CKASGGIFR	KNAIS	WVRQAPG QGLEWMG	GIIAIFGTA NYAQKFQG	RVTITADDSSTNTVYME LTSIRYEDTAVYYCAR	GPNNYENYFD F	WQGTL VTVSS
49	F083-115	QVQLVQ SGAE	VKPGSSVKVS CKASGGIFR	KSAIT	WVRQAPG QGLEWMG	GIIAIFGTT NYAQKFQD	RVTITADDSSTNTVYME LTSIRYEDTAVYYCAR	GPNNYESYLD F	WQGTT VTVSS
47	F083-308	QVQLVQ SGAE	VKPGSSVKVS CKASGGIFR	SHAIS	WVRQAPG QGLEWMG	GIIAIFGTT HYAQQFQG	RVTITADESTSTVYME LSTLRSEDSTAVYYCAR	GPNNYESYFD N	WQGTL VTVSS
48	F083-389	QVQLVQ SGAE	VKPGSSVKVS CKASGDIFN	KFAIT	WVRQAPG QGLEWMG	GITALFATT SYAQKFQD	RVTINWDESTTAFME LSSLRPEDTAVYYCAR	GPNNYETYLD N	WQGTL VTVSS
3	F081-281	QVQLVQ SGSE	VKPGSSVKVS CSFKASGGIIS	KYAIT	WVRQAPG QGLEWMG	GIIAIFGST NYAQKFQG	RLTITSDESTSTAYME LSSLTSEDSTAVYYCGR	GPNNYESHLD Y	WQGTL VTVSS
35	F082-117	QVQLVQ SGSE	VKPGSSVKVS CKSSGGILR	RSAIS	WVRQAPG QGLEWMG	GIIAIFGTT KYAQKFQG	RITITADESTNTVHME LSSLRPDDTAVYYCAG	GPNNYVSYFD S	WQGTL VTVSS
39	F082-237	QVQLVQ SGAE	VKPGSSVKVS CKASGGIFN	KYGIS	WVRQAPG QGLEWMG	GIIAIFGTT NYAQKFQG	RVTISADESSTTVYME LSSLTSEDSTAVYYCAR	GNTYSSSYFD Q	WQGTL VTVSS
54	F083-354	QVQLVQ SGSE	VKPGSSVKVS CKASGGIFN	SYGIS	WVRQAPG QGLEWMG	GIIAIFGTT NYAQKFQG	RVTITADDSSTTVYME LSSLTSEDSTAVYYCAR	GSTYSSSYFD Q	WQGTL VTVSS
37	F083-311	QVQLVQ SGSE	VKPGSSVKVS CKASGGIFR	TNAIS	YVRQAPG QGLEWMG	GITAIFGTP NYAQKFQG	RVTITADESTSTVYME LGSITSEDSTAVYYCAT	SGTYVVSYFD S	WQGTL VTVSS
41	F081-107	QVQLVQ SGAE	VKPGSSVKVS CKASGGIFR	KNAIS	YVRQAPG QGLEWMG	GITAIFGTP NYAQKFQG	RITISADESTNTVYME LGSITSEDSTAVYYCAT	SGTYVVSYLD S	WQGTL VTVSS
52	F083-328	QVQLVQ SGAE	VKPGSSVKLS CKASGGTLR	SYALS	WVRQAPG EGLEWMG	GISAIFNTA TYAQNQQG	RVTITADESTNTFYLE VSSLRSDDTAVYYCAT	SGTYVVSFFD Y	WQGTL VTVSS

Fig. 5 (continued)

40	F081-264	EVQLVE SGAE	VKPKGSSVKVS CKASGGHFN	AYGIS	WVRQAPG QGLEWMG	GIVALFGTT NYAQKLQG	RVITITADASTNTVYME LTSLSRDDTAVYYCAR	SGSYYPDYFQ Y	WGQGTI VTVSS
42	F083-249	QVQLVQ SGSE	VKKPGSSVKVS CKASGVTF	SYAIS	WVRQAPG QGLEWMG	GISPMFGTT RYAQKFQG	RVITITADESTRTGEME LSSLSRSGDTAVYYCAR	SPTYYPGALD M	WGQGTI VTVSS
55	F083-305	EVQLVE SGAE	VKPKGSSVKVS CKASGSIFS	NYAIS	WVRQAPG QGLEWMG	GIVPMFGTT RFAQKFQG	RVITITADESRSTAYME LNNLISEDATVYYCAR	APLIYNWYFD L	WGRGTI VTVSS
56	F083-318	EVQLVQ SGAE	VKKPGSSVKVS CQASGSIFS	NYAIN	WVRQAPG QGLEWMG	GIVPIFGTT RFAQKFQG	RLTITADEPRSTAYME LNNLISEDATVYYCAR	APLIYNWYD L	WGRGTI VTVSS
57	F083-103	QVQLQQ SGAD	VKKAGSSVKVS CKASGRFTG	NYAIS	WVRQAPG QGLEWMG	GITPIFGAA NYAQKFQG	RVTISADLSTRMVYMD LSSLSRDDTAFYYCAG	HPTYHYGSAM DY	WGQGTI VTVSS
58	F083-307	QVQLQQ SGAD	VKKPGSSVKVS CKASGGTGF	NYAIS	WVRQAPG QGLEWMG	GITPIFGPA NYAQRFQG	RVTISADISTRTAYME LSSLSRSEDATVYYCAR	HPTYYFGSAM EY	WGQGTI VTVSS
60	F083-373	QVQLVQ SGAD	VKKPGSSVRVS CKASGRFTG	NYAIS	WVRQAPG QGLEWMG	GITPIFGAA NYAQKFQG	RVTISADLSTTMVYMD LSSLSRDDTAFYYCAG	HPTYYYGSPM DY	WGQGTI VTVSS
59	F083-351	QVQLVQ SGAD	VKKAGSSVKVS CKASGRFTG	NYAIS	WVRQAPG QGLEWMG	GITPIFGAA NYAQKFQG	RVTISADLSTRMVYMD LSSLSRDDTAFYYCAG	HPMYHYGSAM DY	WGQGTI VTVSS
61	F083-302	QVQLVQ SGAE	VKKPGSSVKVS CEASGATFS	SNAFS	WVRQAPG QGLEWMG	GIITMFRKA EYAKKFQG	RVITITAGELGSTAYME VRSLTFEDTAVYYCAR	HSGYHLIGYF DS	WGQGTI VTVSS
62	F083-349	QVQLVQ SGAE	VRKPGSSVKVS CKASGVIFI	KFAIS	WVRQAPG QGLEWMG	GIIPMFGTT NYAQKFQG	RVITITADGSTNTVYME LSSLTSEDATVYYCAK	EEGYYGSGP LDS	WGQGTI VTVSS
63	F083-336	QVQLQQ SGAE	VKQPGSSVKVS CKASGGIFR	SN AIS	WVRQAPG QGLEWMG	GIVALFGTA NYAQKFQG	RVITITADESTSTVYME LSSLSRSEDATVYYCAR	NSGYHISGFY LDY	WGQGTI VTVSS
38	F082-338	QVQLQE SGAE	VKKPGSSVKVS CKASGGPFR	SH AIS	WVRQAAG QGLEWMG	GITAVFGTA NYAQKFQG	RVITITADESTNIVSME LSSLSRSEDATVYYCAR	SLGYHTQYNG MDV	WGQGTI VTVSS
43	F081-007	QVQLQQ SGAE	VKKPGSSVKVS CKASGGIFR	KNAIS	WVRQAPG QGLEWMG	GISAIFGTA NYAQKFQG	RVITITADESSNTVYMD LSRLRSEDATVYYCAS	HPTYHFDKSG YRFDS	WGQGTI VTVSS
64	F083-301	QVQLVQ SGAE	VKKPGSSVKVS CKASGGIFN	SN AIS	WVRQAPG QGLEWMG	GIIGIFGTA NYAQKFQG	RVITIAADQSTNTVYME LSSLTSEDATVYFCAR	SRGYSFGYGT DYFDY	WGQGTI VTVSS
65	F083-366	QVQLVQ SGSE	VKKPGSSVKVS CKASRGIFS	SYAIS	WVRQAPG QGLEWMG	AVIPMFGTL KYAENFQG	RITISADKMSAAVME LSSLSRSEDATVYYCAR	NYGSGTYFN DAFDI	WGQGTI VTVSS
44	F081-008	QVQLVQ SGAE	VKKPGSSVKVS CKASGGTFS	SFSTYTI S	WVRQAPG QGLEWMG	RSIPLLGIT NYAQKFQG	RVITITADISTSTAYME LSSLSRSEDATVYYCAR	YQSSDYNNSE YFQH	WGQGTI VTVSS


Fig. 5 (continued)

Date of blood collection	A/Suita/1/2009H1N1pdm		A/Brisbane/59/2007(H1N1)		A/Indonesia/5/2005(H5N1)	
	HI	VN 50	HI	VN 50	HI	VN 50
2009.10.30	<40	<40	<40	40	<40	<40
2009.11.02	<20	40	<20	20	<20	<40
2009.11.09	<20	320	<20	80	<20	<40
2009.11.17	80	1280	<20	80	<20	<40
2009.11.23	40	1280	<20	80	<20	<40
2009.11.30	40	1280	<20	80	<20	<40
2009.12.07	40	1280	<20	80	<20	<40
2009.12.14	40	2560	<40	80	<40	<40
						ND

Fig. 6

Date of blood collection	A/Suita/1/2009H1N1pdm			A/Brisbane/59/2007(H1N1)		
	Concentration of K1-18			Concentration of K1-18		
	(µg/mL)			(µg/mL)		
	800	400	0	800	400	0
2009.11.02	<40	<40	40	<20	<20	20
2009.11.09	80	320	320	<40	<40	40
2009.11.17	640	640	1280	40	40	40
2009.11.03	320	640	2560	40	40	40
2009.12.07	320	640	2560	40	40	80
2009.12.14	320	320	2560	<40	40	80

Fig. 7






Fig. 8 B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2014/071591

A. CLASSIFICATION OF SUBJECT MATTER

G01N33/53(2006.01)i, G01N33/569(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01N33/53, G01N33/569

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2014

Kokai Jitsuyo Shinan Koho 1971-2014 Toroku Jitsuyo Shinan Koho 1994-2014

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

JSTPlus/JMEDPlus/JST7580 (JDreamIII), CAlplus/MEDLINE/EMBASE/BIOSIS (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nobuko OHSHIMA et al., Naturally Occurring Antibodies in Humans Can Neutralize a Variety of Influenza Virus Strains, Including H3, H1, H2, and H5, J. Virol., 2011.08, Vol.85, No.21, P.11048-11057	1-8
Y	Daniel LINGWOOD et al, Structural and genetic basis for development of broadly neutralizing influenza antibodies, Nature, 2012.09.27, Vol.489, No.7417, Page.566-570	1-8
A	Okada, J. et al., Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified in to three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003, Virology, 2010, Vol.397, P.322-330	1-8

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
08 December, 2014 (08.12.14)Date of mailing of the international search report
16 December, 2014 (16.12.14)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2014/071591

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Taia T. WANG & Peter PALESE, Universal epitopes of influenza virus hemagglutinins?, Nature structural & Molecular Biology, 2009.03, Vol.16, No.3, P.233-234	1-8
A	Jianhua SUI et al., Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses, Nat. Struc. Mol. Biol., 2009, Vol.16, P.265-273	1-8
A	WO 2012/029997 A1 (Educational Foundation Fujita Gakuen), 08 March 2012 (08.03.2012), & US 2012/0058124 A1 & EP 2626425 A1 & AU 2011296837 A & CA 2809780 A & KR 10-2013-0062354 A & CN 103476929 A	1-8
A	JP 2010-502207 A (Crucell Holland B.V.), 28 January 2010 (28.01.2010), & WO 2008/028946 A2 & CA 2663388 A & NO 20091321 A & KR 10-2009-0059121 A & CN 101541832 A & EA 200970255 A & AU 2007293662 A & MX 2009002174 A & IL 197390 D & SG 174773 A & NZ 574581 A & DK 2059532 T & HRT P20130163 & ES 2402217 T & PT 2059532 E	1-8
A	Kyosuke NAGATA, "Analysis of the Cellular Gene Product that Confers Resistance to the Virus Infection", The Asahi Glass Foundation Josei Kenkyu Seika Hokoku, 1995.12, vol.1995, pages 283 to 290	1-8

Form PCT/ISA/210 (continuation of second sheet) (July 2009)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2013172902 A [0001]

Non-patent literature cited in the description

- **SKEHEL, J.J. ; WILEY, D.C.** Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Ann. Rev. Biochem.*, 2000, vol. 69, 531-569 [0004]
- **KNOSSOW, M. et al.** Mechanism of neutralization of onfluenza virus infectivity by antibodies. *Virology*, 2002, vol. 302, 294-298 [0004] [0065]
- **OKUNO, Y. ; ISEGAWA, Y. ; SASAO, F. ; UEDA, S.** A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J. Virol.*, 1993, vol. 67, 2552-2558 [0004]
- **FRASER, C. et al.** Pandemic potential of a strain of influenza A (H1N1): early findings. *Science*, 2009, vol. 324, 1557-1561 [0004] [0065]
- **HANCOCK, K. et al.** Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.*, 2009, vol. 361, 1945-1952 [0004]
- **WRAMMERT, J. et al.** Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med.*, 2011, vol. 208, 181-193 [0004] [0065]
- **LI, G.M. et al.** Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. *Proc. Natl. Acad. Sci.*, 2012, vol. 109, 9047-9052 [0004] [0065]
- **SKEHEL, J.J. ; WILEY, D.C.** Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Ann. Rev. Biochem.*, 2000, vol. 69, 531-569 [0065]
- **OKUNO, Y. ; ISEGAWA, Y. ; SASAO, F. ; UEDA, S.** A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *J. Virol.*, 1993, vol. 67, 2552-2558 [0065]
- **HANCOCK, K. et al.** Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. *N. Engl. J. Med.*, 2009, vol. 361, 1945-1952 [0065]
- **OKADA, J. et al.** Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified in to three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. *Virology*, 2010, vol. 397, 322-330 [0065]
- **OKUNO, Y. et al.** Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. *J. Clin. Microbiol.*, 1990, vol. 28, 1308-1313 [0065]
- **OHSHIMA, N. et al.** Naturally occurring antibodies in humans can neutralize a variety of influenza viral strains, including H3, H1, H2, and H5. *J. Virol.*, 2011, vol. 85, 11048-11057 [0065]
- **ITO, W. ; KUROSAWA, Y.** Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A. *J. Biol. Chem.*, 1993, vol. 268, 20668-20675 [0065]
- **SUI, J. et al.** Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nat. Struc. Mol. Biol.*, 2009, vol. 16, 265-273 [0065]
- **EKIERT, D.C. et al.** Antibody recognition of a highly conserved influenza virus epitope. *Science*, 2009, vol. 324, 246-251 [0065]
- **OKADA, J. et al.** Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man. *J. Gen. Virol.*, 2011, vol. 92, 326-335 [0065]

专利名称(译)	确定对流感病毒的抗性的方法		
公开(公告)号	EP3037819A4	公开(公告)日	2017-03-29
申请号	EP2014838699	申请日	2014-08-18
[标]申请(专利权)人(译)	学校法人藤田学园		
申请(专利权)人(译)	藤田保健卫生大学		
当前申请(专利权)人(译)	藤田保健卫生大学		
[标]发明人	KUROSAWA YOSHIKAZU OHSHIMA NOBUKO		
发明人	KUROSAWA, YOSHIKAZU OHSHIMA, NOBUKO		
IPC分类号	G01N33/53 G01N33/569 C07K16/10 G01N33/68		
CPC分类号	G01N33/686 C07K16/1018 C07K2317/21 C07K2317/55 C07K2317/565 C07K2317/76 G01N33/56983 G01N2333/11		
优先权	2013172902 2013-08-23 JP		
其他公开文献	EP3037819A1		
外部链接	Espacenet		

摘要(译)

提供了一种提供有效手段作为处理流感病毒大流行的对策的方法。使用源自受试者的生物样品中VH1-69基因的抗体的存在或作为指示，确定对A型流感病毒的抗性。